

Curriculum Vitae

Personal Information

Full Name: *Nizal Sarrafzadegan*

Sex: *Female*

Nationality: *Iranian*

Office Address: *Isfahan Cardiovascular Research Institute*

P.O Box: *81465-1148*

Isfahan, Iran

Office Telephone: *+ 98 31 33377888 , 33377889*

Fax: *98-31-33373435*

E-mail: *nsarrafzadegan@gmail.com*

crc@mui.ac.ir

Language Ability: *Persian, English and Arabic*

Education:

- Subspecialty, Fellowship in Cardiology, Tehran and Isfahan Universities of Medical Sciences, Iran. 1991-1993
- Specialty in Internal Medicine. Isfahan University of Medical Sciences, Iran. 1985-1989
- M.D Degree, Isfahan University of Medical Sciences. 1985

Academic Appointments:

- Affiliate Professor, School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. 2014-2019
- Visiting Professor, School of Population and Public Health & Cardiology Division Hospitals, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. 2013-2014
- Visiting Professor, Faculty of Medicine, McGill University, Montreal, Quebec, Canada. 2003-2004
- Full Professor of Medicine, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. 2004-Present
- Clinical Associate Professor of Medicine, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. 1997
- Clinical Assistant Professor of Medicine, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. 1990

Employer: Isfahan University of Medical Sciences, Faculty of Medicine, Isfahan, IRAN.

- Type of employment: Permanent employment.

- Specific duties and responsibilities:

- 1) Teaching medical students, Cardiology/Internal Medicine residents and fellows.
- 2) Supervising thesis of Cardiology residents/fellows or other MS.or PhD in related fields
- 3) Research,with emphasis on all types of Preventive Cardiology and Cardiac Rehabilitation,Cardiovascular Health Promotion,public health,risk factors like tobacco, hypertension,dyslipidemia, obesity, diabetes and metabolic syndrom

Fellowship:

- Fellow of the “Ten Days Teaching Seminar on Cardiovascular Diseases Prevention and Control”. International Society and Federation of Cardiology (ISFC), Munich, Germany. 1996

- International fellow, The Scientific Council of Epidemiology and Prevention, American Heart Association. 1998
- Founder fellow, International College of Cardiology (FICN) 1999
- Fellow of the International Academy of Cardiovascular Sciences, Canada 2002
- Fellow of the American Society of Angiology, USA 2005

Academic awards and distinctions:

- Outstanding Research Award of the Year, the Ministry of Health and Medical Education. 1992
- Outstanding Research Award of the Year, Isfahan University of Medical Sciences. 1993
- Outstanding Assistant Prof. of the Year Award, Isfahan University of Medical Sciences. 1994
- Has been selected for Who's Who in America. 1997
- Special Presidential Award, by the Board of Directors of the International College of Nutrition. 1998
- Outstanding Woman Award of the Year, the Governor of Isfahan. 1999
- Outstanding Researcher of the Year 2001 Award, Isfahan University of Medical Sciences and Health Treatment Services in Isfahan. 2001
- Iranian Presidential Award for the Year's National Razi Research Festival. 2001
- Outstanding Physician of the Year- Social Security Assurance Service Award, Iran. 2002
- Outstanding Physician of the Year- I.R of IRAN Medical Council Award. Isfahan, Iran 2002
- Merit & Worth Medal from International Research Academy of Cardiovascular Sciences, Winnipeg, Canada. 2001
- Merit & Worth Medal from Eastern Mediterranean Region Atherosclerosis Association, Cairo, Egypt. 2000
- Outstanding Women of the Year 2003 in Isfahan, Iran. 2003
- Presidential Award, the National Research Razi Festival in Clinical Sciences. 2003
- Provincial Outstanding Researcher Award, Isfahan, Iran. 2003
- Presidential Medal of Honor (in the field of Merit & Management), Tehran, Iran. 2004

- Provincial Outstanding Award, Governor General of Isfahan, Iran. 2005
- Isfahan University of Medical Sciences, Research Chair Award, Isfahan, Iran. 2006
- Distinctive Researcher of the Country, the Ministry of Science and Technology, National Research Festival. 2008
- Governness General for Research Award 2009
- Elected Citizen Award, Municipality of Isfahan, Isfahan, Iran. 2008
- Selected as the Top Face of the Province, Isfahan, Iran 2010
- Presidential Award, the National Research Razi Festival, Health Promotion Committee, Tehran, Iran 2011
- Iranian Academy of Medical Sciences Award, Tehran, Iran 2011
- Governor General for Environment Protection Award, Tehran, Iran 2011
- Iranian Academy of Medical Sciences Award, Dr. Hadavi Award, Tehran, Iran 2011
- Outstanding Research Award of the Year, Isfahan University of Medical Sciences, Isfahan, Iran 2012
- Selected Author of the book of the year, Office of Culture and Islamic Guidance, Isfahan, Iran 2013
- Top Researcher of Isfahan University of Medical Sciences in the Fields of Having Most Papers and Highest Citations, Isfahan, Iran 2013
- Outstanding Research Award of the Year 2014 for Ranking the Highest International Collaborations and Grants Obtained from national and international Sources, Isfahan, Iran 2014
- WHO Prize for NCD Prevetion and Control, WHO, EMRO 2016
- Distinguished Scientist of the Year in Isfahan University of Medical Scineces, Isfahan, Iran 2016
- Distinguished Researcher of the Year , Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran 2016

Previous and Current Positions:

- Director of Seddigheh Tahereh Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. 2004-Present
- Founder and Director, Isfahan Cardiovascular Research Centre, WHO Collaborating Center, Isfahan University of Medical Sciences, Isfahan, Iran. 1994-Present

- Member, Research Council, Deputy of Research, Isfahan University of Medical Sciences, Isfahan, Iran. 1993- 2003
2007-Present
- Consultant, Deputy of Research, Ministry of Health and Medical Education in Iran. 1992-2003
- Member, Research Committee, Isfahan Faculty of Medicine, Isfahan University of Medical Sciences. 1991-2003
- Member, National Committee on Cardiovascular Disease Prevention, the Ministry of Health and Medical Education in Iran. 1995-1998
- Member, National Committee of Policy Making of Cardiovascular Diseases Prevention. Deputy of Health, Iranian Ministry of Health. 1995-1997
- Member of the National Academic Exam “Board of Cardiology” in Iran. 1997-2003
- Member, National Committee for “Tobacco Control”, Deputy of Research, Ministry of Health in Iran. 2005-2007
- Member, National Committee of Non-Communicable Diseases Prevention and Control, the Ministry of Health in Iran. 2005-2007
- Member, Cardiovascular Commission of Isfahan Forensic Medicine. 2010
- Fonder & Secretary of the National Network on Cardiovascular Disease. 2011-Present
- Member, Clinical Committee of Medical Razi Research Festival, Ministry of Health & Medical Education, Tehran, Iran. 2003-2012
- Member of Research Committee of National Institute of Health Research, Tehran, Iran 2012
- Member, National Committee of Cohort Studies. 2013-Present
- Member, Isfahan University of Medical Sciences High Council. 2014-Present
- Founder Member of the Board of the National Institute of Development of Research in Medical Sciences(NIMAD), Ministry of Health & Medical Education, Tehran, Iran. 2014-Present
- Chair, National Working Group on Cardiovascular Disease Registry 2016

Founder/Member of National Societies:

- Founder and Secretary General, Iranian Heart Foundation, Tehran, Iran. 1999-Present
- Founder and Member of Board of Directors, Iranian chapter of “Heart Friends Around the World”, Isfahan, Iran. 1999-2015
- Vice President of Iranian Chapter of “Heart Friends Around the World”, Isfahan, 2015-2017

Iran.

- Founder and Member of Board of Directors, “Food, Industry and Healthy Community” society, Isfahan, Iran. 2006-2015
- President of the “Food, Industry and Healthy Community” society, Isfahan, Iran. 2015-2017
- Founder and Executive Manager of Sepahan Healthy Heart Diet Company 2012-2014
- Founder and vice-chair of the “Sepahan Foundation of Heart Health Research”. 2012-Present
- Chair of “The first Eastern Mediterranean Congress on Heart Health in Isfahan, Iran 4-7 May 1997”. 1997
- Co-Chair of “The Second Eastern Mediterranean Congress on Heart Health in Beirut, Lebanon 4-7 May 2000”. 2000
- Vice-President of “The Third Eastern Mediterranean Congress on Heart Health in Cairo”, Egypt, 10-13 April 2002. 2002
- Member, Clinical Committee, Razi National Research Festival, the Ministry of Health and Medical Education, Tehran, Iran. 2000-2005
- Chair, Medical Council, Sheikh Bahae Provincial Research Festival, Isfahan, Iran. 1999-2002
- Member, Iranian Heart Association, Tehran, Iran. 1998-Present
- Member, Iranian Society of Internal Medicine, Tehran, Iran. 1994-Present
- Member, Research Council, National Research Center, Ministry of Health and Medical Education, Tehran, Iran. 2000-2003
- Principle Investigator and Director, “Isfahan Healthy Heart Program”: The “National Programme for Cardiovascular Disease Prevention and Control in Iran”. 1999-2007
- Organizer or Coordinator in organizing more than 20 international meetings by Isfahan Cardiovascular Research Center- many of these meetings have been organized in collaboration with international organizations such as the “World Health Organization” or the “World Heart Federation”. 1995-Present

Principle Investigator (PI) or CO-PI or Collaborator in International Studies/Grants:

1. Zyban as an effective smoking cessation aid for patients following an acute coronary syndrome, The ZESCA Trail. McGill University, Jewish General Hospital, Montreal/Canada. (National PI) 2004-2008
2. Strengthening the links between research, practice and public policy to reduce the burden of tobacco, ICE Grant. McGill and Montreal Universities, 2004-2006

Montreal/Canada. (Collaborator)

3. Prevention of recurrent myocardial infarction & stroke. (WHO PREMIS Study). The World Health Organization (WHO), Geneva/Switzerland. (National PI) 2002-2005
4. The International Antismoking Campaign, Quit & Win. National Public Health Institute, Helsinki/Finland. (National PI) 1998-2006
5. Assessment of Cost-Effectiveness of several strategies of early diagnosis in patients with acute chest pain and non-conclusive Electrocardiogram (ASSENCE Trial) Udine University, Udine/Italy. (National PI) 1998-2000
6. Word Pacing Survey, Sydney, Australia, Sydney/Australia. (Collaborator) 1998-2000
7. International Task Force for Coronary Heart Disease Prevention and Control, Munster/Germany. 1999-2005
8. Genetic polymorphism of the caucasus population and their geographic neighbors on the mollecular level, Liepzig/Germany. (PI) 2001-2003
9. Seed Grant from World Health Organization, the United Nations Foundation for "Comprehensive Tobacco Control & Prevention Program Among Iranian Women & Adolescent" Project. CDC, Atlanta/USA. (PI) 2000-2001
10. Global Health Professional Survey of the WHO and Iranian Heart Foundation, (WHO Study). The World Health Organization, Geneva/Switzerland. (National PI) 2001-2003
11. Physician Hypertension Survey. The Eastern Mediterranean Network on Heart Health. (PI) 2002
12. WHO Grant for the Evaluation of "Isfahan Healthy Heart Programme", a Community-based Program for Chronic Disease Prevention and Control, WHO, Geneva /Switzerland. (PI) 2002-2003
13. Studying the "Genetics of Premature Coronary Heart Disease", Yale University, New Haven /USA. 2004-2006
14. COBALT Study (Correlation between abdominal obesity, lipoproteins and transfatty aids), Isfahan Cardiovascular Research Center and Mike Rosenbloom Laboratory for Cardiovascular Research, Montreal/Canada. (PI) 2005-2007
15. WHO Risk Prediction Chart for Predicting Cardiovascular Diseases, WHO, Geneva, Switzerland. (PI) 2005-2007
16. GAAMI Study (Gluteal – abdominal adipocyte morphology in ischemic patients) Isfahan Cardiovascular Research Center and Mike Rosenbloom Laboratory for Cardiovascular Research, Montreal/Canada. (PI) 2006-2008
17. Apolipoproteins B & A Standardization with North-West Lipid Metabolism and Diabetes Research Laboratories, Washington DC, USA. 2006
18. Glycemic index & glycemic load as risk factors of type 2 diabetes Mellitus in Iranian Population, Gent University, Belgium. (Co-Supervisor) 2007

- | | |
|---|--------------|
| 19. World Heart Federation Children's Project Micro-Grant on Sustainability of "Interventions for NCDs prevention", World Heart Federation, Switzerland.(National PI) | 2010 |
| 20. Designing a Suitable Model and Advocacy Package for Salt Consumption Reduction at the Population Level & High Risk Groups, WHO Grant. (PI) | 2011-2012 |
| 21. Developing "Suitable National Model for Self Care of Cardiac Patients". WHO/Ministry of Health(MoH) Grant. (PI) | 2011-2012 |
| 22. International Atherosclerosis Society/Pfizer Grant on Dyslipidemia, International Atherosclerosis Society. (PI) | 2013-Present |
| 23. "Smoking Prevention and Cessation Interventions in Low and Middle Income Countries" McGill University, Montreal, Quebec, Canada.(CO-PI) | 2014 |
| 24. "Intensive Medical Treatment of Angina with Normal Angiography (IMT)", Division of Cardiology, Vancouver General Hospital, UBC, BC, Canada.(CO-PI) | 2014 |
| 25. "Validity and Reproducibility of Food Frequency Questionnaire for Assessment of Sodium/Salt Intake, Food Group Contribution in Sodium/Salt Intake", MoH/WHO, Iran. (PI) | 2013-2015 |
| 26. Development of "A Five Years Multi Sectorial National Action Plan for Salt Intake Reduction", WHO/MoH Grant.(National PI) | 2014 |
| 27. "Design & Implementation of National Registry of Cardiovascular Disease & Coronary Interventions". MoH, Tehran, Iran.(PI) | 2014-2016 |
| 28. "Cardiac Rehabilitation Delivery Model for Low-resource Settings: A consensus Statement". York University, Toronto, Canada. (Vice-Chair of primary writing panel) | 2013-2016 |
| 29. "Assessing the Feasibility of Running a Cardiac Rehabilitation Program in a middle-income Country". York University, Toronto, Canada. (CO-PI) | 2015 |
| 30. Vit D & Metabolic Syndrome, Meta-analysis & Systematic Review. Griffin University, Australia. (CO-Supervisor) | 2015 |

Membership in Advisory Board / Scientific Committees of International

Societies and Academic Bodies:

- | | |
|--|-----------|
| - Founder and Chair of the Eastern Mediterranean Network on Heart Health. | 1997-2008 |
| - Member, European Society of Rehabilitation of Cardiac Patients. | 1997-2000 |
| - Member in the Scientific Committee of "Heart Friends around the World", Italy. | 1998-2004 |
| - Member in the Scientific Committee, Council on Epidemiology and Prevention, International Society and Federation of Cardiology(ISFC), Geneva, Switzerland. | 2002-2005 |
| - Member, Rehabilitation Committee, Asian Pacific Society of Cardiology. | 1999 |

- Founder and Member, International College of Cardiology, India. 1999
- Member of International Task Force on Cardiovascular Disease in Women, USA. 2000
- Member of American Diabetes Association, Professional Section, USA. 2001
- Member of International Advisory Board of “Coronary Heart Disease Prevention in South Asia”. 2002
- Member of International Society of Hypertension. 2003
- Member of International Task Force on Coronary Heart Disease Prevention & Control, Germany. 2001
- Honorary Member, Policy Making Committee in American Cancer Association, USA. 2000
- Member Scientific Board, Grand Challenges in Chronic Non-communicable Disease. Oxford Health Alliance, UK. 2004-2008
- Member of the Advisory Board of Ovations, United Health Group Initiative, USA. 2006-2008
- Member of Scientific Expert Panel of “Women and Heart Disease”, World Heart Federation. Geneva, Switzerland. 2006
- Authority Responsible of External Evaluation Group of “Considering Polypill Role in Cardiovascular Diseases of Aged & Middle-aged Iranians”. Study by Tehran University of Medical Sciences. 2007
- Member of the International Cardiovascular Health (IC Health) Executive and Scientific Committees, India. 2005-2008
- Member of “International Cardiovascular Health” (IC Health) Foundation, Switzerland. 2005-2012
- Member of the Advisory Board of Communities in Health (CIH) Project, UK. 2007-2008
- Member of Oxford Health Alliance Community Action to Prevent Chronic Disease (CAP COD) Project, UK. 2007-2008
- Member of ProCor’s (Web-based International Program for Cardiovascular Disease Prevention) International Advisory Council, Brooklyn, USA. 2008-2010
- Member of the WHO Community Guidelines on Physical Activity for Health 2010
- Faculty member of Prevention of Non-communicable Diseases Seminars, Finland 2009-2011
- Member of NCD Network for Research & Training in WHO/Eastern Mediterranean Region(EMR) 2011
- Member of Scientific Committee/Target group leader of the World Congress of Cardiology (WCC) in Dubai and Melbourne 2012-2014

- Member of the International Council of Cardiovascular Prevention and Rehabilitation, (ICCPR) 2012-Present
- Member of the Eastern Mediterranean Network of Experts in Surveillance of Non-Communicable Diseases 2014
- Fellow of the International Academy of Cardiovascular Sciences(IACS) 2003- Present

Editorial Board Member of Peer-Reviewed Journals

- Member of Editorial Board of “Cardiovascular Disease Prevention & Control” Journal. The official Journal of the “World Heart Federation”, Geneva, Switzerland. 2004-2009
- Correspondence foreign member in the Advisory Board of “Journal of Angiology”, France. 2003-2005
- Member, Editorial Advisory Board, “Tobacco Control Journal”, British Medical Journal, London, UK. 2001-2003
- Member, Advisory Board of “Nature Reviews Cardiology” Journal. London,UK 2012-Present
- Member, Editorial Board of “Datasets Papers in Medicine” Journal 2012-Present
- Member of the Editorial Board of the “Scientific World Journal”, USA 2012-Present
- Member of International Advisory Board of the Journal of American College of Cardiology(JACC), USA 2014-Present
- Member of Editorial Board of “Journal of Blood Disorder”, USA 2014-Present
- Responsible Director/Chief Editor of ARYA Atherosclerosis Journal. The official journal of Isfahan Cardiovascular Research Center. 2004-Present
- Member, Editorial Board of “Iranian Journal of Diabetes & Lipid Disorders”, Shaheed Behishti University, Tehran, Iran. 2003-Present
- Member, Editorial Board of “Bulletin of Emergency Medicine and Trauma” Shiraz, Iran 2012-Present
- Member, Editorial Board of “Qazveen University of Medical Sciences Journal”, Qazveen, Iran. 2004-Present
- Member of Editorial Board of the Journal of “Tehran Heart Center”, Tehran, Iran. 2005
- Member of the Editorial Board of the Journal of “Jahrom University of Medical Sciences”, Jahrom, Iran. 2006-Present
- Member of Editorial Board of “Developing World Epidemiology”, Journal, Tehran, Iran. 2009
- Member of Editorial Board of “International Journal of Preventive Medicine” Isfahan, Iran 2010-Present

- Member, Editorial Board of Research in Medical Sciences. Journal of Isfahan University of Medical Sciences, Isfahan, Iran. 2010-2012
- Member of Editorial Board of SM Journal of Community Medicine (SMCM) 2015
- Member of Editorial Board of Scientifica 2015
- Member of Editorial Board of Annals of Cardiovascular Diseases 2016
- Member of Editorial Board of Annals of Obesity & Disorders 2016
- Member for Editorial Board of the International Journal of Cardiology (IJC). 2016
- Member for Editorial Board of Austin Internal Medicine. 2016
- Reviewer of more than 15 international and national journals

Invited Speaker/Lecturer

A- International Meetings:

1. Sarrafzadegan N, et al. "Sex-based difference in the awareness and treatment of isolated systolic hypertension in elderly people in Isfahan/Iran" In: The 1st Asia Pacific Congress on Hypertension (Nov 29th - Dec 3rd), Surat: India, 1997.
2. Sarrafzadegan N, et al. "Cardiovascular disease situation and preventive actions in Iran" In: The 13th Biennial Congress of Cardiology. (Dec 3-6) Karachi: Pakistan, 1997.
3. Sarrafzadegan N, et al. "Cardiovascular disease situation in the Eastern Mediterranean Region" In: Cardiology Update: (7-10 October), Venice: Italy, 1998.
4. Sarrafzadegan N, et al. "Priorities of cardiovascular diseases prevention in Iran" In: International Congress on Atherosclerosis, Hypertension & Coronary Artery Disease (14-16 Oct), New Delhi: India, 1999.
5. Sarrafzadegan N, et al. "The regional profile of rheumatic and myocardial disease in the Middle East" In: International Conference on Heart Health in Developing Countries (10-14 Oct), New Delhi: India, 1999.
6. Sarrafzadegan N, et al. "Cardiac rehabilitation and secondary prevention: Present situation in Eastern Mediterranean region, the solutions to the problem" In: 12th Asian Pacific Congress of Cardiology (17-21 Oct), Pakistan: Lahore, 1999.
7. Sarrafzadegan N, et al. "Prevalence rate of coronary artery disease risk factors in the Eastern Mediterranean Region with special reference to Iran" In: International Congress on Atherosclerosis, Hypertension & Coronary Artery Disease, (14-16 Oct), New Delhi: India, 1999.
8. Sarrafzadegan N, et al. "Cardiac rehabilitation in the developing countries, current practices, problems of Implementation and solutions" In: The 7th World Congress of Cardiac Rehabilitation and Secondary Prevention (20-24 Feb), Manila: Philippines, 2000.

9. Sarrafzadegan N, et al, "Evaluation of the effectiveness of rehabilitation program in rheumatic heart disease" In: The 7th World Congress of Cardiac Rehabilitation and Secondary Prevention, (20-24 Feb) Manila: Philippines, 2000.
10. Sarrafzadegan N, et al. "Cardiovascular disease prevention in the EMR: population-based and/or high-risk approach" In: The Second Eastern Mediterranean Congress on Heart Health. (4-7 May), Beirut: Lebanon, 2000.
11. Sarrafzadegan N, Sajadi F. "Hypertension and diabetes prevalence awareness, treatment and control among Eastern Mediterranean women" In: The First International Conference on Women, Heart Disease and Stroke. (7-10 May), Vancouver: Canada, 2000.
12. Sarrafzadegan N. "The effectiveness of community-based programmes on non-communicable disease prevention & control" In: 2nd Global Forum on NCD Prevention & Control by WHO (4-6 November) Shanghai: China, 2002.
13. Sarrafzadegan N. "The prevalence of cardiovascular risk factors in hypertensive patients in Iran": In 19th WHL Council Conference & Workshop on Hypertension & Obesity (22 June) Prague, Czech Republic, 2002.
14. Sarrafzadegan N. "Implementation of community-based interventions for chronic disease prevention". (March) Muscat: Oman, 2003.
15. Sarrafzadegan N. "Evidence-based prevention of coronary heart disease". In: 1st International Medicine Update Symposium. (December 6-9), Riyadh: Saudi Arabia, 2004.
16. Sarrafzadegan N. "The WHO STEPwise surveillance of risk factors in the EMR". In: XII International Conference on Heart Health (June), Milan: Italy 2004.
17. Sarrafzadegan N. "Isfahan Healthy Heart Program: Practical model of community-based programme". In: Oxford Vision 2020. (Sep.) Oxford: UK, 2004.
18. Sarrafzadegan N. "Coronary heart disease prevention and control". In: Global Forum on Cardiovascular Diseases. (June), Winnipeg, Manitoba: Canada, 2004.
19. Sarrafzadegan N. "Community-based interventional programs for CVD prevention". MacMaster University (August) Hamilton: Canada, 2004.
20. Sarrafzadegan N. "Preventive cardiology, what is the role of health care authorities?", (Sep 22) Dubai: UAE, 2005.
21. Sarrafzadegan N. "Isfahan Healthy Heart Programme: Evaluation model for comprehensive community-based intervention programme on non-communicable disease prevention & health promotion in developing countries". In: Sixth International Conference on Preventive Cardiology. (May 21-25), Iguacu: Brazil, 2005.
22. Sarrafzadegan N. "Oxford health alliance meeting". In: Yale University, (Nov) Newhaven: USA, 2005.
23. Sarrafzadegan N. "Isfahan Healthy Heart Program: Model for community-based programs on NCD prevention and health promotion". In: Nandi-WHO International Visitor Programme, (October) Mauritius, 2005.
24. Sarrafzadegan N. "Integrated chronic disease prevention into health services". In: Nandi-WHO International Visitor Programme, Mauritius, 2005.

25. Sarrafzadegan N. "Isfahan Healthy Heart Program (IHHP): Practical model of community-based interventional programs". (July) Boston: USA, 2006.
26. Sarrafzadegan N. "Community-based programs for chronic diseases prevention and health promotion". In: Harvard University, School of Public Health, (July) Boston: USA, 2006.
27. Sarrafzadegan N. "Community initiatives in the reduction of the burden of cardiovascular disease". In: World & European Congress of Cardiology", (September) Barcelona, Spain, 2006.
28. Sarrafzadegan N. "Practical models for cardiac rehabilitation programmes in developing countries, How to setup cardiac rehabilitation programmes in low and middle-income countries". In: World & European Congress of Cardiology, (September) Barcelona, Spain, 2006.
29. Sarrafzadegan N. "Neglected health threats: Managing the prevention and treatment of global chronic disease". In: Clinton Global Initiative (GCI), (20-22 September), New York: USA, 2006.
30. Sarrafzadegan N. "Wellcome Trust Workshop on Secondary Prevention of Cardiovascular Disease in Low and Middle Income Countries", (June 6-8), London: UK, 2007.
31. Sarrafzadegan N. "Strategic meeting of grand challenges for chronic non-communicable disease", (October 23-24) London, UK, 2007.
32. Sarrafzadegan N. "Lunch of the Lancet series special edition on chronic disease:" (December 3-4) London, UK, 2007.
33. Sarrafzadegan N. "Models of cardiac rehabilitation programs for low and middle income countries", (May 18-21), Buenos Aires, Argentina, 2008.
34. Sarrafzadegan N. "Isfahan Healthy Heart Program, Iran: A case study of community participation". In: Geneva Forum 2008, (25-28 May) Geneva, 2008.
35. Sarrafzadegan N. "Building Trust on Obesity Control Workshop", (Nov. 11-15) Toronto, Canada, 2008.
36. Sarrafzadegan N. "Evaluating healthy lifestyle programmes for childhood obesity". In: World Heart Federation Workshop on Obesity in Children, (June 15-16), Geneva, Switzerland, 2009.
37. Sarrafzadegan N. "Evaluation of cardiovascular disease programs". In: 2nd All Africa Conference on Heart Disease, Diabetes, and Stroke in Africa. (September 26-30) Abuja: Nigeria, 2009.
38. Sarrafzadegan N. "The case for cardiovascular health promotion in low & middle income economics". In: 2nd All Africa Conference on Heart Disease, Diabetes, and Stroke in Africa. (September 26-30), Abuja: Nigeria, 2009.
39. Sarrafzadegan N. "Addressing CVD in low resource settings". In: 2nd All Africa Conference on Heart Disease, Diabetes, and Stroke in Africa. (September 26-30), Abuja: Nigeria, 2009.
40. Sarrafzadegan N. "Isfahan Healthy Heart Program-CHD prevention experience from Iran". In: Prevention of Non Communicable Disease Seminar, (March 15-19) Helsinki, Finland 2010.
41. Sarrafzadegan N. "CHD prevention experiences from Iran". In: Emirates CVD Society, (April 10) Dubai, UAE 2011.

42. Sarrafzadegan N. "Isfahan Healthy Heart Program-CHD prevention experience from Iran". In: Prevention of Non Communicable Disease Seminar, (March 14-18) Helsinki, Finland 2011.
43. Sarrafzadegan N. "Barriers for implementation of prevention cardiology". In: 2nd Annual Emirates Cardiac Society Congress, (October 22-23) Dubai, UAE 2011.
44. Sarrafzadegan N. "Isfahan Healthy Heart Program". In: 2nd Annual Emirates Cardiac Society Congress, (October 22-23) Dubai, UAE 2011.
45. Sarrafzadegan N. "Healthy diet & physical activity promotion in schools & pre-schools". In: World Congress of Cardiology (WCC), (April 18-21) Dubai, UAE 2012.
46. Sarrafzadegan N. "Confronting the threat of sheeshah in Iran". In: World Congress of Cardiology (WCC), (April 18-21) Dubai, UAE 2012.
47. Sarrafzadegan N. "Isfahan Healthy Heart Program – The Iranian experience". In: World Congress of Cardiology (WCC), (April 18-21) Dubai, UAE 2012.
48. Sarrafzadegan N. "Blood pressure variability: mechanisms and how to measure it". In: World Congress of Cardiology (WCC), (April 18-21) Dubai, UAE 2012.
49. Sarrafzadegan N. "Priorities in non communicable disease prevention" In: WHO/Emirates Cardiac Society, (January 9-11) Dubai, UAE 2014.
50. Sarrafzadegan N. "Early results of polypill large trial for primary prevention: Iranian experience". In: World Congress of Cardiology (WCC), (May 4-7) Melbourne, Australia 2014.
51. Sarrafzadegan N. "Strategies for development of CVD disease prevention in Asia". In: World Congress of Cardiology (WCC), (May 4-7) Melbourne, Australia 2014.
52. Sarrafzadegan N. "Barriers and facilitators of cardiovascular preventive programs?". In: World Congress of Cardiology (WCC), (May 4-7) Melbourne, Australia 2014.
53. Sarrafzadegan N. "Community-based Intervention: impact on prevention". In: 4th International Conference on Women, Heart Disease and Stroke, (May 4) Melbourne, Australia 2014.
54. Sarrafzadegan N. "Barriers to cardiac rehabilitation programmes in LMIC". In: World Congress of Cardiology (WCC), (May 4-7) Melbourne, Australia 2014.
55. Sarrafzadegan N. "Risk factor surveys in programme planning and evaluation". In: World Congress of Cardiology (WCC), (May 4-7) Melbourne, Australia 2014.
56. Sarrafzadegan N. "POLY-IRAN Update". In: Cardiovascular Combination Pill. Global Summit, 2014 from Concept to Reality, (May 8) Melbourne, Australia 2014.
57. Sarrafzadegan N. "Cardiovascular disease prevention in women: community-based approach". In: The World Congress of Cardiology, (May 4-8) Melbourne, Australia 2014.
58. Sarrafzadegan N. "Non-communicable disease crisis: United Nations, WHO, and global responses". In: UBC/SPPH, (June 9) British Columbia, Canada 2014.
59. Sarrafzadegan N. "Polypill: Is it a Solution for primary & secondary prevention of cardiovascular disease?". In: UBC Division of Cardiology Grand Rounds, (July 17) British Columbia, Canada 2014.

60. Sarrafzadegan N. "The Isfahan Healthy Heart Program Model in Iran". In: International Symposium of Prevention of Cardiovascular Disease and Risk Factors of NCD in Tunisia, (September 27) Souses, Tunisia 2014.
61. Sarrafzadegan N. "Managing cardiovascular risk factors in the Middle East". In: The 2014 Canadian Cardiovascular Congress. (October 25-28) Vancouver, Canada 2014.
62. Sarrafzadegan N. " Demonstration programmes as tools for national action: A case study from Iran". In: World Congress of Cardiology (WCC) 2016. (June 4-8) Mexicocity, Mexic 2016

National Meetings:

63. Sarrafzadegan N. "Epidemiologic study atherosclerosis risk factors in Isfahan". In: First Internal Medicine Assistants, National Seminar on Atherosclerosis, (May) Isfahan: Iran, 1989.
64. Sarrafzadegan N. "Risk factors of myocardial infarction in 2792 patients in Isfahan". In: 2nd National Congress of Internal Medicine, (March) Shiraz, Iran, 1990.
65. Sarrafzadegan N. "Risk factors of cardiovascular disease in young patients". In: 2nd National Congress of Internal Medicine, (March) Shiraz, Iran, 1990.
66. Sarrafzadegan N. "Myocardial infarction and contraceptive use in women". In: 4th Annual Congress of Iranian Heart Association, Tehran: Iran, 1990.
67. Sarrafzadegan N. "Lipoproteins and coronary heart disease". In: 3rd National Congress of Internal Medicine, Mashhad, Iran, March, 1992.
68. Sarrafzadegan N. "Hyperlipidemia type and family history in an urban area in Isfahan". In: 5th National Congress of Internal Medicine, Isfahan, Iran, May 1994.
69. Sarrafzadegan N. "The levels of blood pressure in adults in Isfahan". In: 5th National Congress of Internal Medical, Isfahan; Iran 1994.
70. Sarrafzadegan N. "The relationship between passive smoking and coronary heart disease". In: 8th National Congress of Iranian Heart Association, Tehran: Iran, 1995.
71. Sarrafzadegan N. "Comparison between coronary heart disease risk factors of patients who died before Hospitalization with those who were hospitalized". In: 6th National Congress of Internal Medicine, Tabriz, Iran, 1995.
72. Sarrafzadegan N. "Can magnesium, fibrinogen and CPK-MB Serum levels predict future complications in patients with myocardial infarction?". In: 9th Annual Congress of Iranian Heart Association, (May) Tehran, Iran, 1996.
73. Sarrafzadegan N. "Sex-based differences in the mean levels and prevalence of high blood pressure in Iran". In: 9th Annual Congress of Iranian Heart Association, (May) Tehran, Iran 1996.
74. Sarrafzadegan N. "Differences in the prevalence of hypertension in urban and rural areas in Iran". In: 7th National Congress of Internal Medicine,(June) Tehran, Iran, June 1996.
75. Sarrafzadegan N. "Practical model of preventive strategies of non-communicable disease". Hamedan University of Medical Sciences, Hamedan, Iran, July 2007.

76. Sarrafzadegan N. "Isfahan Healthy Heart Program: practical model for CVD prevention". Shiraz University of Medical Sciences, Shiraz, Iran, November 2007.
77. Sarrafzadegan N. "Acquaintance with methods of getting grant sources". Isfahan University of Medical Sciences, Isfahan, Iran, 15 December 2008.
78. Sarrafzadegan N. "The first workshop on national & international research grant sources". Kashan University of Medical Sciences, Isfahan, Iran, 20 December 2008.
79. Sarrafzadegan N. "Review of Isfahan Healthy Heart Program experiences". National Institute of Nutrition, Tehran, Iran, 11 October 2008.
80. Sarrafzadegan N. "Methods of getting research grant sources". Faculty of Nursing & Midwifery, Tehran University, Iran, 29 October 2008.
81. Sarrafzadegan N. "Cardiovascular disease and its relationship with air pollution". Isfahan Governor General, Isfahan, Iran, 14 April 2008.
82. Sarrafzadegan N. "The effect of cigarette smoking on inflammatory markers and apolipoproteins". In: First Regional (EMRO) Congress on Tobacco and Health, Kish Island, Iran, 28-30 January 2009.
83. Sarrafzadegan N. "Cardiovascular disease epidemic: A growing challenge in low and middle income countries". In: 3rd Middle East (Iran-Arab) Cardiovascular Congress, Kish Island, Iran, 12-15 March 2009.
84. Sarrafzadegan N. "The growing burden of cardiovascular disease in modern world: strategies for prevention". In: 4th Middle East Cardiovascular Congress (MECC 2010), Kish Island, Iran, 3-5 March 2010.
85. Sarrafzadegan N. "Current status of preventive cardiology in Iran's". In: 4th Symposium on Updates in CV Diseases, Shiraz, Iran, 27-30 April 2010.
86. Sarrafzadegan N. "Cardiovascular disease & urbanization". In: Urbanization & Health Seminar, Tehran, Iran, 24-25 April 2010.
87. Sarrafzadegan N. "Global warning of cardiovascular disease epidemic & call for prevention". In: 5th Middle East Cardiovascular Congress (MECC 2011), Kish Island, Iran, 23-25 Feb 2011.
88. Sarrafzadegan N. "Challenges facing preventive cardiology: from guidelines to clinical practice". In: 17th Congress of Iranian Heart Association, Tehran, Iran, 10-13 May 2011.
89. Sarrafzadegan N. "Strategies for cardiovascular disease prevention & control: experiences from Iran". In: 17th Congress of Iranian Heart Association, Tehran, Iran, 10-13 May 2011.
90. Sarrafzadegan N. "Importance of screening of cardiovascular disease in world today". In: 1st National Congress of Advanced Screening in Medicine, Mashhad, Iran, 25-26 May 2011.
91. Sarrafzadegan N. "CVD situation in Iran". In: 1st International Congress on "Coronary Artery Diseases" Update, Mashhad, Iran, 5-7 October 2011.
92. Sarrafzadegan N. "Women & tobacco control". In: The 5th International Congress on Pulmonary Diseases & Intensive Care & Tuberculosis, Tehran, Iran, 15-18 October 2011.

93. Sarrafzadegan N. "Preventive modalities in heart disease". In: The Fifth Seminar of Fars Heart Foundation, Shiraz, Iran, 24-27 April, 2012.
94. Sarrafzadegan N. "Prevention, treatment & control of cardiovascular disease: Isfahan Healthy Heart Program". In: 2nd National and 1st International Conference of Best Practices of Primary Health Care, Bojnurd, Iran, 30 October– 1 November, 2012.
95. Sarrafzadegan N. "Cardiovascular priority in 2013: control your blood pressure". In: 2nd International Congress on Coronary Artery Diseases Updates, Mashhad, Iran, 1-3 May, 2013.
96. Sarrafzadegan N. "Cardiovascular disease epidemic; global warning and call for prevention". In: 1st International Cardiac Surgery Congress in Mazandaran, Sari, Iran, 9-10 May, 2013.
97. Sarrafzadegan N. "Cardiovascular disease in women". In: 2nd International Conference on Women's Health, Shiraz, Iran, 2 May, 2013.
98. Sarrafzadegan N. "Salt intake and reduction strategies in Iran". In: Meeting with WHO Delegation for Nutrition Program, Tehran, Iran, 3 September, 2014.
99. Sarrafzadegan N. "Introduction to Healthy Heart Program: in advocacy on NCD prevention & control". In: WHO-MoH, Tehran, Iran, 2 September, 2014.
100. Sarrafzadegan N. "Global prospect of cardiac rehabilitation". In: 1st International Congress of Cardiac Rehabilitation from Research to Practice, Isfahan, Iran, 21 October, 2014.
101. Sarrafzadegan N. "How to obtain research grants from internal and external Non-Governmental sources". In: The Research Festival, Isfahan University of Medical Sciences, Isfahan, Iran, 30 December, 2014.
102. Sarrafzadegan N. "Advances in heart failure research in the last decade". In: The One Day Seminar on Heart Failure, Isfahan, Iran, 1st January, 2015.
103. Sarrafzadegan N. "Current Status of Cardiovascular Disease in Iran". In: The 4th International Preventive Congress, Shiraz, Iran, 30 September, 2015.
104. Sarrafzadegan N. "Large scale studies supported by the national network of CVD research". In: The 4th Iranian Cardiovascular Joint Congress, Tehran, Iran, 1-4 March, 2016
105. Sarrafzadegan N. "CVD Crisis and global responses". In: The 4th Iranian Cardiovascular Joint Congress, Tehran, Iran, 1-4 March, 2016
106. Sarrafzadegan N. "Cardiovascular Disease: Global, Regional, National Situation and Future Strategies". In: 7th Symposium on Updates in C.V Diseases, Kowsar Hospital Symposium, Shiraz, Iran, 26-29 April, 2016
107. Sarrafzadegan N. "Persian Registry of Cardiovascular Disease (PROVE)". In: the 2nd Seminar of Diseases Registry and health outcomes. Tehran, Iran, 2-4 May, 2016

Participation in World Health Organization Consultation Meetings as WHO Advisor/Consultant:

1. WHO Consultation Meeting on "Cardiovascular Disease Prevention". Cyprus, Nicosia, 1995.
2. WHO Consultation Meeting on "Framework for Chronic Disease Prevention". Geneva, Switzerland, 1999.

3. WHO Consultation Meeting on “National Plans for Cardiovascular Disease Prevention”. Cairo, Egypt, 2000.
4. 2nd Global Forum on Non-Communicable Diseases Prevention & Control by WHO. Shanghai, China, 2002.
5. 2nd Meeting on Surveillance of Non-Communicable Diseases, Beirut, Lebanon, 2002
6. Quit&Win/WHO consultation meeting on tobacco control,Barcelona,Spain 2003
7. WHO Global Strategy for Diet and Physical Activity consultation meeting,Geneva,2003
8. Implementation of Community-Based Interventions for Chronic Disease Prevention. Muscat, Oman, 2003.
9. IV WHO Global Forum on Chronic Disease Prevention and Control, Ottawa, Canada, Nov. 2004.
10. Japan–WHO International Visitors Programme on NCD Prevention & Control, Tokyo, Japan, April 2005.
11. Nandi-WHO International Visitor Programme, Mauritius, May 2005.
12. 2nd WHO Expert Consultation Meeting on “Preventing Chronic Diseases: a Framework For Country Action”. Hong Kong, Nov. 2007.
13. WHO meeting on “Prioritized Research Agenda for Prevention & Control of Non-Communicable Diseases”. Geneva, Switzerland, Sep. 2008.
14. WHO meeting on “Development of a Prioritized Research Agenda for Prevention and Control of Non-Communicable Diseases (NCD)”. WHO, Geneva, Switzerland, Oct. 2010
15. WHO Consultating meeting to “Strengthening Partnerships for Integrated Prevention & Control of Non-Communicable Diseases”. Dubai, United Arab Emirates, April 2011.
16. WHO and John Hopkins University Meeting on “JHSPH-WHO Eastern Mediterranean Regional Tobacco Control Leadership”. Cairo, Egypt, Nov. 2012.
17. Sarrafzadegan N. “National Strategies that Adapt WHO Guides for Salt & fat Intake Reduction”. In: The First NCD Congress in the UAE (Non-Communicable Chronic Disease), (January 9-11) Dubai, UAE 2014.
18. WHO meeting on “Experts’ Workshop on Advising Countries on Noncommunicable Diseases (NCD) Surveillance & Developing the Network of Regional Experts”. Cairo, Egypt, Sep. 2014.
19. NCD Alliance/WHO EMRO Capacity Development Workshop. Amman, Jordan, 15-16 Aug. 2016
20. Event to launch the ‘Global Hearts Initiative’, WHO/CDC meeting. New York, USA 22 Sep. 2016

Publications

Books or Chapters in Books:

1. Hennekens CH. H, Buring J.E. Epidemiology in Medicine (Translation), 1998.
2. Maghsoodloo. S. Cardiac Rehabilitation .Teimoorzadeh Publisher . (supervision) 2001.
3. Burgarella F. The HEARTBook. (translated), 2001.
4. Sarrafadegan N, Sajadi F. Hypertension and diabetes prevalence, awareness, treatment and control in the Eastern Mediterranean Region: with special reference to Iran. Frontiers Cardiovascular Health. Edited by N.S.Dhalla, A. Chokalingam, H I Berkowitz & P.K.Singal. Kluwar Academic Publishers, Boston, 2003.
5. Sarrafadegan N, et al. Effective strategies and actions for control and prevention of non-communicable diseases in Iran “Isfahan Healthy Heart Program”. (First IHHP Series Book),) Isfahan University of Medical Sciences Publisher ,Isfahan , 2007.
6. Sarrafadegan N, Alikhassi H. Isfahan Healthy Heart Program from design to implementation (Second IHHP Series Book)) ,Isfahan University of Medical Sciences Publisher ,Isfahan, 2008.
7. Global Recommendations on Physical Activity for Health, World Health Organization, 2010 (peer reviewer)
8. Sarrafadegan N. Educational Package of Isfahan Healthy Heart Program(3rd IHHP Series Book) Isfahan University of Medical Sciences Publisher ,Isfahan, 2011
9. Sarrafadegan N, Rabiei K. Participation Compliance and Outcomes of Outpatient Cardiac Rehabilitation Programs Among Women in Low Resource Settings. Cardiac Rehabilitation, Nova Publisher Inc ,US, 2010; Chapter 8:185-199
10. Planning, Implementation and Evaluation of Non-Communicable Diseases Prevention and Control. WHO Publisher, 2010.

Published Articles In Peer-Reviewed Journals

International

1. Sarrafadegan N, Adib M. Association of HLA system and coronary artery disesse.Iranian Journal of Medical Science 1995; 20(3&4):117-119.
2. Sarrafadegan N, Amininik S. Blood pressure pattern in urban and rural area: Isfahan Hypertension Study. Journal of Human Hypertension 1997; 11(7): 424-28.
3. Sarrafadegan N. Heart rate: a predictor of early mortality in patients with myocardial infarction. Iranian Journal of Medical Sciences 1997; 11(4): 295-8.
4. Boshtam M, Rafiei M, Sarrafadegan N. Obesity and associated cardiovascular risk factors in Isfahan population: Isfahan Cardiovascular Risk Factor Survey. Atheroscleroza 1997; 1(4):7-11.
5. Asgary S, Sarrafadegan N, Ghassemi N, Ghanadi A, Sajadi E, Sajadi F, Naderi Gh. Antihyperlipidemic effects of Crataegus Curvisepala lind. Intercontinental Cardiology 1998; 7(2): 73-75.

6. Nematbakhsh M, Rajabi P, Soltani SH, Sarrafazadegan N, et al. Estrogen attenuates endothelial permeability and fatty streaks in cholesterol- fed male rabbit aorta. *Atherosclerosis* 1998; 2(1): 3-7.
7. Rafiei M, Boshtam M, Sarrafazadegan N. Comparison of knowledge, attitude and practice of Isfahan population regarding the role of nutrition on coronary artery disease. *Intercontinental Cardiology* 1998; 7(1): 13-16.
8. Sarrafazadegan N, Alikhasi H, Abdar N. "Cardiovascular disease situation and preventive actions in Iran". *Atherosclerosis* 1998; 136, Supplement 1: S53-S53.
9. Sarrafazadegan N, Sajadi F, Mohammadifard F. "Antihyperlipidemic effect of crataegus Curvisepala Lind". *Atherosclerosis* 1998; 136, Supplement 1: S35-S35.
10. Mohammadifard N, Sarrafazadegan N, Jalali A, Rafiei M, et al. Food and nutrients intake among adults of Isfahan. *South Asian J of Preventive Cardiology* 1998; 2: 59-64.
11. Sarrafazadegan N, Boshtam M, Rafiei M. Risk factors for coronary heart disease in Isfahan. *Europe J of Pub Health* 1999; 9(1): 20-26.
12. Sarrafazadegan N, Sayed-Tabatabaei FA, Bashardoost N et al. The prevalence of coronary artery disease in an urban population in Isfahan, Iran. *Acta Cardiologica* 1999; 54(5): 257-263.
13. Sarrafazadegan N, Boshtam M, Malekafzali H, et al. Secular trends of mortality from cardiovascular disease in Iran: with special reference to Isfahan. *Acta Cardiologica* 1999; 54(6): 327-333.
14. Sarrafazadegan N, Boshtam M, Najafian J, Poorshams A, Samarian S. "Hypertension and dyslipidemia among Iranian people". *Atherosclerosis* 1999;144, Supplement 1: S150-S151.
15. Sarrafazadegan N, Malekafzali H, Tabatabaei F, Tafazoli F, Boshtam M. "Cardiovascular disease in Iranian women, trends in incidence and mortality from CHD 1990-1996 in Isfahan". *Atherosclerosis* 1999;144, Supplement 1: S187-S188.
16. Sarrafazadegan N, Mohammadifard N, Sajjadi F, Abdar N. "Abdominal obesity and lipoprotein disturbances among Iranians". *Atherosclerosis* 1999;144,: Supplement 1:S 156-S156.
17. Sarrafazadegan N, Naderi GH, Asgary S, Zarie M, Samarian H. "Hemostatic factors, apolipoproteins and lipoprotein(a) levels among Iranians". *Atherosclerosis* 1999;144, Supplement 1: S106-S107.
18. Sarrafazadegan N, Zarei M, Naderi GH, Asgari S, Samarian H, Karimi A, Fatehi-far R. "The effect of fasting during the month of holy Ramadan on apolipoproteins and coagulation system". *Atherosclerosis* 1999;144, Supplement 1 S174-S174.
19. Sarrafazadegan N, Zarei M, Samarian H, Naderi GH, Asgary S, Fatehi-far R. "The relation between apolipoproteins, lipoprotein(a) and hemostatic factors". *Atherosclerosis* 1999;144 Supplement 1,: S106-S106.
20. Sarrafazadegan N, Jalali A, Alikhasi H, Samarian H, Mohammadifard N, Sajjadi F, Boshtam M. "Central obesity, nutritional status and lipid disturbances in Iranian women". *Atherosclerosis* 1999;144, Supplement 1: S174-S174.
21. Sarrafazadegan N, Kelishadi R, Hashmipoor H, Samarian H, Naderi Gh, Asgari S. "Lipoprotein and apoprotein levels among Iranian high risk children". *Atherosclerosis* 1999;144, Supplement 1:S 136-S136.
22. Asgary S, Naderi Gh, Sarrafazadegan N, Haeri MR, Boshtam B, Zarei M. "The free radical inhibitory effect of some flavonoids". *Atherosclerosis* 1999;144 Supplement 1,: S188-S188.

23. Boshtam M, Rafiei M, Sarrafazadegan N, Asgary S, Khalili S, Zarfeshani S. "Smoking prevalence and its relation with some cardiovascular risk factors". *Atherosclerosis* 1999;144, Supplement 1: S188-S189.
24. Mohammadifard N, Sarrafazadegan N, Sajadi F, Abdar N. "Body fat distribution, serum lipids, blood pressure and coronary artery disease in adults of Isfahan, Iran". *Atherosclerosis* 1999;144 Supplement 1,:S 159-S159.
25. Sarrafazadegan N, Boshtam M, Mostafavi S, Rafiei M. "Prevalence of hypertension and associated risk factors in Isfahan". *Eastern Mediterranean Health J* 1999; 5(5): 992-1001.
26. Asgary S, Sarrafazadegan N, Naderi Gh, et al. "Anti-oxidant effect of Flavonoids on hemoglobin glycosylation". *Pharmaceutica Acta Helvetica* 1999; 73: 223-26.
27. Rafiei M, Boshtam M, Sarrafazadegan N. "Lipid profiles in the Isfahan population: Isfahan Cardiovascular Risk Factors Survey". *Eastern Mediterranean Health Journal* 1999; 5(4):766-776.
28. Boshtam M, Sarrafazadegan N, Rafiei M, et al. "The relation between CK-MB/CK activity index and serum magnesium and fibrinogen in myocardial infarction". *Pakistan J Cardiol* 1999; 10(2-3): 47-53.
29. Sarrafazadegan N, Atashi M, Naderi Gh, Baghai AM, et al. "The effect of fasting in Ramadan on the values and interrelations between biochemical, coagulation and hematological factors". *Annals of Saudi Medicine* 2000; 20(5-6): 377-381.
30. Sarrafazadegan N, Singh RB, Rakesh Sharma, et al. "The Asian ethnic paradox: differences in dietary fat intake and risk of coronary artery disease in Iranian and Indian young - elderly populations". *J of Nutr and Environ Med* 2000; 11: 113-119.
31. Asgary S, Nadery GH, Sarrafazadegan N, et al. "Antihypertensive and antihyperlipidemic effects of *Achillea Wilhelmsii*". *Drugs Under Experimental & Clinical Research* 2000;26(3): 89-94.
32. Boshtam M, Rafiei M, Sarrafazadegan N, Asgary S. "Smoking prevalence and its combination with cardiovascular risk factors". *Acta Medica Iranica* 2000; 38(2): 115-20.
33. Singh RB, Suh IL, Singh VP, Chaithiraphan S, Laothavorn P, Sy RG, Babilonia NA, Rahman ARA, Sheikh S, Tomlinson B, and Sarrafazadegan N. "Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention". *J of Human Hypertension* 2000; 14:749-763.
34. Pourshams A, Mohammadifard N, Asgary S, Golshadi I, Sarrafazadegan N. "Evaluation of the international 'Quit and Win' contest 1998 in Isfahan". *Iran Arc Irn Med* 2000; 3(2):75-77.
35. Boshtam M, Sadeghi K, Sarrafazadegan N, et al. "The effect of supervised exercise training on type of psychological characteristics and physical fitness after myocardial infarction". *Acta Medica Iranica* 2000; 38(4):224- 228.
36. Sarrafazadegan N, Amiri M, Magsoodloo S. "Helicobacter pylori relation to acute myocardial infarction in an Iranian sample". *Coronary Health Care* 2001; 5: 1-6.
37. Kelishadi R, Hashemipour M, Sarrafazadegan N, et al. "Trend of atherosclerosis risk factors in children of Isfahan". *Asian Cardiovascular Thorac Ann* 2001; 9: (36-40).
38. Garak Yaraghi M, Kianjoo M, Mortazavi M, Sarrafazadegan N, Shemirani H, Shah Parian M. "Efficacy of GIKM (Glucose, Insulin, Potassium and Magnesium) therapy in the management of myocardial infarction compared to current thrombolytic therapy: A double blind randomized clinical trial". *J Res Med Sci.* 2001;6(3):233-228.

39. Tavassoli AA, Behrad-Manesh S, Dehgan H, Sarrafazadegan N, et al. "Assessment of cost effectiveness of several strategies of early diagnosis in patients with acute chest pain & non conclusive electrocardiogram: The Iranian experience". *Journal of Molecular & Cellular & Cardiology* 2008; 33(6):A121-A121.
40. Boshtam M, Rafiei M, Sadeghi M, Sarrafazadegan N. Vitamin E can reduce blood pressure in mild hypertensive. *Int J vit Nut Res* 2002; 72(5): 309-14.
41. Kelishadi R, Sarrafazadegan N, Nadery Gh, et al. Atherosclerosis risk factors in children & adolescents with or without family history of premature coronary heart disease. *Medical Sciences Monit* 2002; 8(6): 425-9.
42. Boshtam M, Sarrafazadegan N, Kelishadi R. "Relation of Serum Lipids, apolipoproteins & vitamin D of serum in children with high risk families regarding CVD & their comprehensive to the control group". *J Res Med Sci(JRMS)* 2002; 7(2):122-127.
43. Naderi Gh, Asgary S, Ani M, Sarrafazadegan N, et al. Study on the effect of some pure plant volatile oils on the affinity of native & oxidized LDL and LDL oxide to its receptor in adrenal cell's surfaces: *J Medicinal Plants Research* 2002; 1(1): 11-18.
44. Asgary S, Naderi Gh, Sarrafazadegan N, et al. The inhibitory effect of pure flavonoid on invitro protein glycosylation. *J Herbal Pharmacotherapy* 2002; 2(2):47-55.
45. Sarrafazadegan N, Sadri G, Malek Afzali H, Baghaei M, Mohammadi Fard N, Shahrokhi S, Toloioe H, Poormoghaddas M, Sadeghi M, Tavassoli A, Rafiei M, Kelishadi R, Rabiei K, Bashardoost N, Boshtam M, Asgary S, Naderi G, Changiz T, Yousefie A. Isfahan Healthy Heart Programme: a comprehensive integrated community-based programme for cardiovascular disease prevention and control. Design, methods and initial experience. *Acta Cardiol* 2003 Aug;58(4):309-20.
46. Naderi Gh, Asgary S, Sarrafazadegan N, Shirvany H. Anti-oxidant effect of flavonoids on the susceptibility of LDL oxidation. *Molecular and Cellular Biochemistry* 2003; 246: 193-196.
47. Asgary S, Naderi Gh, Sarrafazadegan N, Gharypour M. In vitro effect of nicotine and cotinine on the susceptibility of LDL oxidation and hemoglobin glycosylation. *Molecular and Cellular Biochemistry* 2003; 246: 117-120.
48. Fard NM, Sarrafazadegan N, Sajadi F, Rafiei M, Abdar. Effect of cardiac rehabilitation on lipid profile. *J Assoc Physicians India* 2003; 5:5-12.
49. Kelishadi R, Hashemipoor M, Sarrafazadegan N, et al. Obesity & associated modifiable environmental factors in Iranian adolescents: Isfahan Healthy Heart Program-Heart Health Promotion from Childhood. *Pediatrics International* 2003; 45(4):435-442.
50. Sarrafazadegan N. "Factor analysis of the metabolic syndrome among Iranian smokers and non-smokers". *Atherosclerosis Supplements* 2003;4(2): 47-47.
51. Khosravi A, Kelishadi R, Sarrafazadegan N, Ansari R. "Trends in blood pressure level, prevalence of hypertension and its care in Isfahan, Iran (1991-2001)". *Atherosclerosis Supplements* 2003;4(2): 39-3.
52. Khami MA, Sarrafazadegan N, Boshtam M, Bashardoost N, Malekafzali H, Tafazoli F. "Cardiovascular disease in Iran: Mortality, prevalence and risk factors over 15 years". *Atherosclerosis Supplements* 2003;4(2): 112-112.
53. Fard NM, Mehrabian F, Sarrafazadegan N, Sajadi F. "Fat modified diets during pregnancy & lactation & serum lipids after birth. *Indian J Pediatr* 2004; 71(8):683-7.
54. Sarrafazadegan N, Boshtam M, Shahrokhi Sh, et al. "Tobacco use among Iranian women & adolescents". *European J of Public Health* 2004; 14(1):76-85.

55. Kelishadi R, Sarrafazadegan N, Hashemipoor M et al. "Dietary fat intake and lipid profiles of Iranian adolescents: IHHP-HHPC". *Prev Med* 2004; 39:760-766.
56. Kelishadi R, Sarrafazadegan N, Sadri GH et al. "Smoking, adolescents & health. Isfahan Health Heart Program- Heart Health Promotion from childhood". *Asian Pacific Journal of Public Health* 2004; 16(1):15-22.
57. Nasidze I, Ling EYS, Quinque D, Dupanloup I, Cordaux R, Rychkov S, Naumova O, Zhukova O, Sarrafazadegan N, et al. "Mitochondrial DNA and Y-Chromosome variation in the Caucasus". *Annals of Human Genetics* 2004; 68(3):205-221
58. Naderi Gh, Asgary S, Ani M, Sarrafazadegan N, et al. "Effect of some volatile oils on the affinity of intact and oxidized low-density lipoproteins for adrenal cell surface receptors". *Mol Cell Biochem* 2004; 267:59-66.
59. Naderi Gh, Asgary S, Sarrafazadegan N, et al. "Antioxidant activity of three extract of Nigra". *Phytotherapy Research* 2004; 18(5):365-369.
60. Pourmoghaddas M, Khosravi A, Kelishadi R, Sarrafazadegan N, Shirani Sh, Ansari R, Sabet B. "Trends in blood pressure level, prevalence and control of hypertension in Isfahan, Iran". *Iranian Heart Journal* 2004; 5(1,2):33-38.
61. Boshtam M, Sarrafazadegan N, Rafiei M, Tafazoli F. Smoking habits among an Iranian population. *Pakistan Journal of Cardiology* 2005; 16(1):23-28.
62. Kelishadi R, Derakhshan R, Sabet B, Sarrafazadegan N, et al. The metabolic syndrome in hypertensive & normotensive subjects: The Isfahan Healthy Heart Programme. *Ann Acad Med Singapore* 2005; 34(3):243-9.
63. Najafian J, Kelishadi R, Sarrafazadegan N, et al. "Mean duration of EKG changes in patients with unstable angina". *ARYA Atherosclerosis Journal*, 2005; 1(2):85-88.
64. Sabet B, Derakhshan R, Sadeghi M, Sarrafazadegan N, et al. "Two -year incidence of acute fatal and non fatal Coronary events and stroke: Iranian Population over 35 Years old". *ARYA Atherosclerosis Journal*, 2005; 1(1):9-14.
65. Baghaie AM, Gharipour M, Mohammadifard N, Sarrafazadegan N. "Secondary Prevention in cardiovascular disease: Closing the gaps". *ARYA Atherosclerosis Journal*, 2005; 1(2):65-67.
66. Gharipour M, Baghaie AM, Rabiei K, Sarrafazadegan N. "Pharmacological treatment, lifestyle modification and awareness in coronary artery and cerebrovascular disease patients". *ARYA Atherosclerosis Journal*, 2006; 1(4):261-265.
67. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, de Graaf J, Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Jungner I, Krauss RM, Kwiterovich P, Marcovina S, Packard CJ, Pearson TA, Reddy KS, Rosenson R, Sarrafazadegan N, Sniderman AD, Stalenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KM. "Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel". *J Intern Med*. 2006; 259(3):247-58.
68. Oveisgharan SH, Shirani SH, Baghaiei AM, Hosseini SH, Sarrafazadegan N. Barthel Index in a Middle East Country: Translation, validity & reability. *Cerebrovascular Disease Journal*. *Cerebrovasc Dis* 2006; 22:350-354.
69. Sarrafazadegan N, Baghaei AM, Sadri GH, Kelishadi R, Malekafzali H, Boshtam M, Amani A, Rabie K, Moatarian A, Rezaeiashtiani A, Paradis G, O'loghlin J. "Isfahan Healthy Heart Program: Evaluation of comprehensive, community-based interventions for non-communicable disease". *Prevention and Control J* 2006; 2(2): 73-84.

70. Adibi P, Sadeghi M, Minakari M, Garak Yarayhi M, Rozati G, Sarrafazadegan N. "Hypertransaminasemia as a risk factor for coronary heart disease: a case-control study". *Journal of Gastroenterology and Hepatology*. 2006; 21:A59-A59.
71. Sarrafazadegan N, Rabiei K, Shirani SH, Kabir A, et al. Drop-out predictors in cardiac rehabilitation programmes and the impact of sex differences among coronary heart disease patients in an Iranian sample: a cohort study. *Clinical Rehabilitation* 2007; 21(4):362-72.
72. Sniderman AD, Bohpal R, Sarrafazadegan N, Tchernof A. Why might South Asians be so susceptible to central obesity & its atherogenic consequences? The adipose tissue overflow hypothesis. *International Journal of Epidemiology* 2007; 36:220-225.
73. Daar A.S, Singer P.A, Persad D.L, Pramming S.K, Matthews D.R, Beaglehole R, Bernstein A, Borysiewicz L.K, Colagiuri S, Ganguly N, Glass R.I, Finegood D.T, Koplan J, Nabel E.G, Sarna G, Sarrafazadegan N, Smith R, Yach D and Bell J. Grand challenges in chronic non-communicable disease. *Nature* 2007; 450:494-496.
74. Oveisgharan Sh, Sarrafazadegan N, Shirani Sh, Khosravi AR, Hosseini Sh. Stroke in Isfahan, Iran: Hospital admission an 28-day case fatality rate. *Cerebrorasc Dis* 2007; 24:495-499.
75. Nucifora G, Budano LP, Sarrafazadegan N, et al. "Comparison of early dobutamine stress echocardiography and exercise electrocardiographic testing for management of patients presenting to the emergency department with chest pain". *Am J Cardiol* 2007; 100(7):1068-1073.
76. Shety P. "Sarrafazadegan N: Leading Cardiovascular Research in Iran". *Lancet* 2007; 18:370(9587):559.
77. Liu W, Garipour M, Asgary S, Sadeghi M, Davis N, Sarrafazadegan N, Mani A. "Lrp6 Mediates Cellular Cholesterol Uptake". *Circulation* 2007; 116:II-183.
78. Sarrafazadegan N, Rabiei K, Kabir A, et al. Changes in lipid profile of patients referred to a cardiac rehabilitation program. *European Journal of Cardiovascular Prevention & Rehabilitation* 2007; 15(4):467-472.
79. Sadeghi M, Roohafza H, Shirani Sh, Poormoghadas M, Kelishadi R, Baghaie AM, Sarrafazadegan N. Diabetes and associated cardiovascular risk factors in Iran: The Isfahan Healthy Heart Programme. *Ann Acad Med Singapore* 2007; 36:175-80.
80. Roohafza H, Sadeghi M, Sarrafazadegan N, et al. Relation between stress and other life style factors. *Stress and Health* 2007; 23(1):23-29.
81. Abdi A, Khosravi A, Sarrafazadegan N, et al. "The effect of low-dose Niacin added to Simvastation on lipoprotein profile". *ARYA Atherosclerosis Journal*, 2007; 3(1):8-13.
82. Javid Hussain Akhtar, Sarrafazadegan N, Mohammadifard N, et al. "Is there any difference between dietary habits in hypertensives, hyperlipidemics, obese, smoker, individuals and the normal population?". *ARYA Atherosclerosis Journal*, 2008; 4(3):112-120.
83. Nazari N, Asgary S, Sarrafazadegan N, et al. "Content of long chain omega-3 fatty acid composition in some Iranian canned fish". *ARYA Atherosclerosis Journal*, 2008; 4(3): 93-97.
84. Sarrafazadegan N, Rezapurian P, Kaypour M, Mohseni M, Sadeghi M, Asgary S & Sabet B. "Prognostic value of infection & inflammation markers for late cardiac events in an Iranian sample". *Eastern Mediterranean Health Journal* 2008; 14(6):1246-1256.
85. Sadeghi M, Sadat Razavi N, Sarrafazadegan N, et al. Early & late effect of high dose Atorvastatin and low dose Atorvastatin on serum C-Reactive protein reduction in non-ST elevation myocardial infarction. *ARYA Atherosclerosis Journal*, 2008; 4(1): 6-12.

86. Sarrafzadegan N, Rabiei K, Kabir A, et al. "Gender differences in risk factors and outcomes after cardiac rehabilitation". *Acta Cardiol* 2008; 63(6): 763-770.
87. Liu W, Mani S, Davis NR, Sarrafzadegan N, KAvatha PB, Mani A. Mutation in EGFP Domain of LDL Receptor-related protein 6 impairs cellular LDL clearance. *Circulation Research* 2008; 103(1):1280-8.
88. Shahrokhi Sh, Kelishadi R, Sarrafzadegan N, et al. "Evaluation of the Quit & Win contest for smoking cessation in the Islamic republic of Iran". *Eastern Mediterranean Health Journal* 2008; 14(6):1270-1279.
89. Asgary S, Sarrafzadegan N, Naderi Gh, et al. "Effect of opium addiction on new and traditional cardiovascular risk factors: do duration of addiction and route of administration matter". *Lipid & Health and Disease* 2008;7:42: 1-5
90. Rafiei M, Boshtam M, Sarrafzadegan N, et al. "The relation between salt intake and blood pressure among Iranians". *Kuwait Medical Journal* 2008; 40(3):191-195.
91. Sarrafzadegan N, Kelishadi R, Baghaei AM, et al. "Metabolic syndrome: An emerging public health problem in Iranian women: Isfahan Healthy Heart Program". *International Journal of Cardiology* 2008; 131(1):90-96.
92. Gharipour M, Kelishadi R, Sarrafzadegan N, et al. "The association of smoking and components of the Metabolic Syndrome in Non-diabetic Patients". *Ann Acad Med Singapore* 2008; 37(11):919-923.
93. Grandi S, Gervais A, Joseph L, O'Loughlin J, Paradis G, Pilote L, Rinfret S, Sarrafzadegan N, et al. "Smoking cessation following coronary syndrome". *Journal of American College of Cardiology* 2008; 51(10):A368-A368 Suppl A MAR 11.
94. Sarrafzadegan N, Sadeghi M, Tavassoli AA, et al. "Sex-differences in the impact of a community-based program for non-communicable disease prevention: The Isfahan Healthy Heart Programme (IHHP)". *Journal of Public Health* 2009; 17:257-263.
95. Sarrafzadegan N, Kelishadi R, Esmailzadeh A, et al. "Do lifestyle interventions work in developing countries? Findings from the Isfahan Healthy Heart Program in Iran". *Bulletin of World Health Organization* 2009; 87:39-50.
96. Rabiei K, Kelishadi R, Sarrafzadegan N, et al. "Process evaluation of a community-based program for prevention and control of communicable disease in a developing country: The Isfahan Healthy Heart Program". *BMC Public Health* 2009; 9:57: 1-14
97. Mohammadifard N, Kelishadi R, Safavi M, Sarrafzadegan N, et al. "Effect of a community-based intervention on nutritional behavior in a developing country setting: the Isfahan Healthy Heart Program. *Public Health Nutr* 2009; 17:1-9.
98. Tabib A, Siadat Z, Sarrafzadegan N, Kelishadi R, Zarfeshani S, Khosravi A. "Smoking and lipids". *Atherosclerosis Supplements* 2009; 10(2):e1062-e1062.
99. Asgary S, Nazari B, Sarrafzadegan N, Saberi S, Azadbakht L, Esmailzadeh A. "Trans fatty acid content of some Iranian commercial food products". *Atherosclerosis Supplements* 2009; 10(2): e759-e759.
100. Gharipour M, Sarrafzadegan N, Siadat S, Maghroun M, Abdolvand A. "Metabolic Syndrome epidemiology based on socioeconomic status: Cross sectional study among Iranian adult population". *Atherosclerosis Supplements* 2009; 10(2): e1352-e1352.
101. Nucifera G, Badano LP, Sarrafzadegan N, et al. "Effect on quality of life of different accelerated diagnostic protocols for management of patients presenting to the emergency department with acute chest pain". *Am J Cardiol* 2009; 103(5):592-7.

102. Sarrafazadegan N, Ashrafi F, Noorbakhsh M, et al. “ Association of breast artery calcification with coronary artery disease & carotid Intima-media thickness in Iranian pre-menopausal women”. *Easter Mediterranean Health J* 2009; 15(6): 1474-1482.
103. Roohafza H, Sadeghi M, Shirani S, Bahonar A, Mackie M, Sarrafazadegan N. “Association of socioeconomic status and lifestyle factors with stress coping strategic in Isfahan Healthy Heart Program”. *Croat Med J* 2009; 50(4):380-6.
104. Sarrafazadegan N, Azadbakht L, Mohammadifar N et al. “Do lifestyle interventions affect dietary diversity score in the general population?” *Public Health Nutrition* 2009; 12(10):1924-1930.
105. Asgary S, Nazari B, Sarrafazadegan N, et al. “Evaluation of fatty acid content of some Iranian fast foods with emphasis on trans fatty acids”. *Asia Pac J Clin Nutr.* 2009; 18(2): 187-92.
106. Solhpour AR, Parkhideh S, Sarrafazadegan N, Asgary S, et al. “Levels of Lipids and Apolipoproteins in Three Cultres”. *Atherosclerosis.* 2009;207(1):200-7
107. Shirani S, Kelishadi R, Sarrafazadegan N, Khosravi A, Sadri GH, et al. Awareness, treatment and control of hypertension, dyslipidemia and diabetes mellitus in an Iranian population: Isfahan Healthy Heart Program. *Easter Mediterranean Health J.* 2009; 15(6):1455-1463.
108. Hashemipour M, Kelishadi R, Shapouri J, Sarrafazadegan N, et al. “Effect of zinc supplementation on insulin resistance and components of the metabolic syndrome in prepubertal obese children”. *Hormones* 2009; 8(4):279-285.
109. Maghzi AH, Etemadifar M, Ramezani MA, Sarrafazadegan N, et al. “Does Ramadan fasting influence the incidence & short-term survival of stroke?”. *Journal of Neurology* 2009; 256:S172-S172.
110. Mosavi E, Gharipour M, Tavassoli A, Sadri GH, Sarrafazadegan N. “Multiparity and risk of metabolic syndrome: Isfahan Healthy Heart Program”. *Metab Syndr Relat Disord* 2009; 7(6): 519-24.
111. Khosravi A, Avesta L, Kelishadi R, Ramezani M, Bahonar A, Heydari H, Tavassoli A, Sarrafazadegan N. Assessment of relation between microalbuminuria and ischemic electrocardiogram in Iranian general population. *ARYA Atherosclerosis Journal* 2009;5(1):27-32.
112. Asgari S, Nazari B, Sarrafazadegan N, et al. “Fatty acid composition of commercially available Iranian edible oils”. *J Res Med Sci.* 2009; 14(4):211-215.
113. Bahonar A, Khosravi A, Esmaelian H, Babak A, Rahmati M, Jamshidi A, Azad M, Daneshvar P, Sarrafazadegan N. Methods of implementing the operational phases of the health professionals education project Isfahan Healthy Heart Program (IHHP-HPEP). *ARYA Atherosclerosis Journal*, 2009;5(3):103-107.
114. Roohafza H, Sarrafazadegan N, Shahn timer M, et al. Are community-based intervention programs effective in the youth population? Results from Isfahan Healthy Heart Program. *ARYA Atherosclerosis Journal*, 2009;5(3):111-117.
115. Sarrafazadegan N, Oveisgharan Sh, Toghianifar N, et al. Acute myocardial infarction in Isfahan, Iran: Hospitalization & 28th day case-fatality rate. *ARYA Atherosclerosis Journal*, 2009;5(3):132-137.
116. Sadeghi M, Tavasoli A, Roohafza H, Sarrafazadegan N. “The relationship between ankle-brachial index and number of involved coronaries in patients with stable angina”. *ARYA Atheroscler* 2010; 6(1):6-10.

117. Sarrafazadegan N, Kelishadi R, Najafian A, et al. "Anthropometric Indices in Association with Cardiometabolic Risk Factors: Findings of the Isfahan Healthy Heart Program. ARYA Atherosclerosis Journal, 2010; 5(4):152-162.
118. Mozafari M, Sadeghi M, Sanei H, Ramezani MA, Golabchi A, Sarrafazadegan N. "Evaluation of leptin and adiponectin levels in patients with stable angina pectoris". ARYA Atherosclerosis Journal, 2010; 6(2):50-55.
119. Baghaei A, Sarrafazadegan N, Rabiei K, et al. How effective are strategies for non-communicable disease prevention & control on high risk population in a developing country Isfahan Healthy Program. Archives of Medical Sciences 2010; 6(1):24-31.
120. Golabchi A, Sarrafazadegan N. "What every cardiologist should know about H1N1?" ARYA Atherosclerosis Journal, 2010; 6(3):117-120.
121. Hajmohammadi T, Sadeghi M, Dashti M, Hashemi M, Saadatnia M, Soghrati M, Talaei M, Sarrafazadegan N. "Relationship between carotid intima-media thickness with some inflammatory biomarkers, ghrelin and adiponectin in Iranians with and without metabolic syndrome in Isfahan cohort study". ARYA Atherosclerosis Journal, 2010; 6(2):56-61.
122. Rabiei K, Kelishadi R, Sarrafazadegan N, Sadri Gh, et al. "Short-term results of community-based interventions for improving physical activity: Isfahan Healthy Heart Program". Archives of Medical Sciences 2010; 6(1):32-39.
123. Shahn timer M, Roohafza H, Sadeghi M, Tavassoli A, Bahonar A, Sarrafazadegan N. "The correlation between lipid profile and stress levels in part central Iran: Isfahan healthy heart program". ARYA Atherosclerosis Journal, 2010; 6(3):101-104.
124. Sarrafazadegan N, Kelishadi R, Siadat ZD, Esmailzadeh A, Solhpour A, Shirani Sh, et al. "Obesity and Cardiometabolic Risk Factors in a representative population of Iranian adolescents and adults in comparison to western population: IHHP". Public Health Nutrition 2010; 13(3):314-323.
125. Cheraghi M, Sadeghi M, Sarrafazadegan N, Pourmoghadas A, Ramezani MA. "Prognostic factors for survival at 6-month follow-up of hospitalized patients with decompensated congestive heart failure". ARYA Atherosclerosis Journal, 2010; 6(3):11-116.
126. Sarrafazadegan N, Toghyanif ar N, Roohafza H, Siadat Z, Mohammadifard N, O'Loughlin J. "Lifestyle-related Determinants of Hookah and Cigarette Smoking In Iranian Adults". J Community Health 2010; 35:36-42.
127. Yousefy AR, Ghassemi GR, Sarrafazadegan N, Mallik S, Baghaei AM, Rabiei K. "Psychometric properties of the WHOQOL-BREF in an Iranian adult sample". Community Ment Health J. 2010;46(2):139-47.
128. Gharipour M, Kelishadi R, Toghyanif ar N, Mackie M, Sarrafazadegan N, Noori F. "Pharmacological Treatment of Cardiovascular Risk Factors in Individuals with Metabolic Syndrome: Findings from the Isfahan Healthy Heart Program. Journal of Hypertension 2010; 28: e107.
129. Roohafza H, Talaei M, Sadeghi M, Mackie M, Sarrafazadegan N. "Association between Acute and Chronic Life Events on Acute Coronary Syndrome: A Case-Control Study". J Cardiovasc Nurs. 2010;25(5):E1-E7.
130. Kelishadi R, Hashemipour M, Sarrafazadegan N, et al. "Effects of a lifestyle modification trial among phenotypically obese metabolically normal and phenotypically obese metabolically abnormal adolescents in comparison with phenotypically normal metabolically obese adolescents". Matern Child Nutr. 2010;6(3):275-86.

131. Bahonar A, Sarrafazadegan N, Kelishadi R, Shirani S, Ramezani MA, Taghdisi MH, Gharipour M. "Association of socioeconomic profiles with cardiovascular risk factors in Iran: the Isfahan Healthy Heart Program". *International Journal of Public Health*. 2010; 56(1):37-44.
132. Tavassoli AA, Gharipour M, Khosravi A, Kelishadi R, Siadat ZD, Bahonar A, Sadri GhH, Sadeghi M, Rabiei K, Sajjadi F, Zarfeshani S, Eshrati B, Shirani Sh, Sarrafazadegan N. Gender differences in obesogenic behaviour, socioeconomic and metabolic factors in a population-based sample of Iranians: The IHHP Study. *J Health Popul Nutr*. 2010; 28(6):602-609.
133. Heidari R, Sadeghi M, Talaei M, Rabiei K, Mohammadifard N, Sarrafazadegan N. Metabolic syndrome in menopausal transition: Isfahan Healthy Heart Program, a population based study. *Diabetology & Metabolic Syndrome* 2010; 2:59.
134. Sarrafazadegan N, Talaei M, Sadeghi M, Kelishadi R, Oveisgharan S, Mohammadifard N, Sajjadi A R, Kabiri P, Marshall T, Thomas G N and Tavassoli A. "The Isfahan Cohort Study: Rationale, methods and main findings". *Journal of Human Hypertension* 2010; 25(9):545-553.
135. Khosravi AR, Kiani Mehr G, Kelishadi R , Shirani S, Gharipour M, Tavassoli A, Noori F, Sarrafazadegan N. "The Impact of a 6-year Comprehensive Community Trial on the Awareness, Treatment and Control Rates of Hypertension in Iran: Experiences from the Isfahan Healthy Heart Program". *BMC Cardiovascular Disorders* 2010; 10:61.
136. Nazari B, Asgary S, Sarrafazadegan N. "Warning about Fatty Acid Compositions in Some Iranian Mayonnaise Salad Dressings". *Int J Prev Med*. 2010;1(2):110-4.
137. Sarrafazadegan N, Sadri G, Melek-Afzali M. "Effect of a 6-year comprehensive community-based program on cardiovascular risk factors: Experiences from demonstration study in a developing country". *Circulation* 2010;122(2): E81-E81.
138. Sarrafazadegan N, Rabiei K, Zarfeshani S. "Lessons learned from failures: Experiences of demonstration program for cardiovascular disease prevention and control". *Circulation* 2010;122(2): E358-E358.
139. Bahonar A, Sarrafazadegan N, Kelishadi R, Ramezani MA, Gharipour M, Shirani S. "Relationship between socioeconomic profiles with cardiovascular risk factors in Iran: The IHHP Study". *Circulation* 2010;122(2): E186-E186.
140. Gharipour M, Sarrafazadegan N, Toghianfar N, Mackie M, Noori F. Metabolic Syndrome: "Patient compliance with drug treatment (Isfahan Healthy Heart Study)". *Circulation* 2010;122(2): E139-E139.
141. Toghianfar N, Sarrafazadegan N, Ramezani MA, Bahonar A, Nouri F. "Smoking cessation advice among hypertensive patients in a population-based sample of Iranian adults (IHHP)". *Circulation* 2010;122(2): E277-E277.
142. Golabchi A, Sarrafazadegan N, Pormoghaddas M. "A woman with Typical Chest Pain and Broken Heart". *J Cardiovasc Thorac Res* 2011; 2(4):31-34.
143. Kelishadi R, Sarrafazadegan N, Sadri GH, Pashmi R, Mohammadifard N, Tavassoli AA, Amani A, Rabiei K, Khosravi A, Bahonar A. "Short-term results of a community-based program on promoting healthy lifestyle for prevention and control of chronic diseases in a developing country setting: Isfahan Healthy Heart Program". *Asia Pac J Public Health*. 2011;23(4):518-33.
144. Roohafza H, Sadeghi M, Shahnaim M, Bahonar A and Sarrafazadegan N. Perceived factors related to cigarette and waterpipe (ghelyan) initiation and maintenance in university students of Iran. *Int J Public Health* 2011; 56:175–180.

145. Roohafza H, Ramezani A, Sadeghi M, Shahnam M, Zolfaghari B, Sarrafazadegan N. "Development and validation of the Stressful Life Event (SLE) questionnaire". *International Journal of Public Health*, 2011; 56(4):441-8.
146. Sarrafazadegan N, Gharipour M, Tavassoli A, et al. "Metabolic syndrome and health-related quality of life in Iranian population". 2011; 16(3):254-261.
147. Gharipour M, Kelishadi R, Toghianifar N, Mackie M, Yazdani M, Noori F, Sarrafazadegan N. "Sex based pharmacological treatment in patients with metabolic syndrome: Findings from the Isfahan healthy heart program". *African Journal of Pharmacy and Pharmacology* 2011; 5(3):311-316.
148. Khosravi A, Pourmoqhadas M, Ostovan M, Kiani Mehr G, Gharipour M, Zakeri S, Soleimani B, Namdari M, Hassanzadeh M, Tavasolli AA, Ghaffari S, Khaledifar A, Roghani F, Khosravi MR, Sarami SH, Kojouri J, Nori F, Khosravi E, Jozan M and Sarrafazadegan N. "The impact of generic form of Clopidogrel on cardiovascular events in patients with coronary artery stent: results of the OPCES study". 2011;16(5):640-50.
149. Samsamshariat S, Basati Gh, Movahedian A, Pourfarzam M, Sarrafazadegan N. "Elevated plasma platelet-activating factor acetylhydrolase activity and its relationship to the presence of coronary artery disease". 2011; 16(5):674-9.
150. Gharipour M, Kelishadi R, Toghianifar N, Tavassoli AA, Khosravi AR, Sajadi F, Sarrafazadegan N. "Socioeconomic disparities and smoking habits in metabolic syndrome: evidence from Isfahan Healthy Heart Program". *Iran Red Crescent Med J*. 2011; 13(8):537-543.
151. Basati Gh, Pourfarzam M, Movahedian A, Samsamshariat S.Z, Sarrafazadegan N. "Reduced plasma adiponectin levels relative to oxidized low density lipoprotein and nitric oxide in coronary artery disease patients". *CLINICAL SCIENCE*, 2011; 66(7):1129-35.
152. Samsamshariat SZ, Basati Gh, Movahedian A, Pourfarzam M, Sarrafazadegan N. "Elevated plasma myeloperoxidase levels in relation to circulating inflammatory markers in coronary artery disease". *Biomarkers Med*. 2011;5(3), 377–385.
153. Tavassoli A, Gharipour M, Toghianifard N, Sarrafazadegan N, et al. "The impact of obesity on hypertension and diabetes control following healthy lifestyle intervention program in a developing country setting". 2011;16(Special Issue):368-376.
154. Golabchi A, Sarrafazadegan N. "Takotsubo cardiomyopathy or broken heart syndrome: A review article". *J Res Med Sci*. 2011;16(3):340-5.
155. Kabir A, Sarrafazadegan N. "The real role of exercise versus medication in lipid profile of patients referred to a cardiac rehabilitation program". *Eur J Cardiovasc Prev Rehabil*. 2011;18(4):680-1.
156. Mendis S, Lindholm LH, Anderson SG, Alwan A, Koju R, Onwubere BJ, Kayani AM, Abeysinghe N, Duneas A, Tabagari S, Fan W, Sarrafazadegan N, Nordet P, Whitworth J, Heagerty A. "Total cardiovascular risk approach to improve efficiency of cardiovascular prevention in resource constrain settings". *J Clin Epidemiol* 2011;64(12):1451-62.
157. Toghianifar N, Sarrafazadegan N, Roohafza H, Sadeghi M, Eshrati B, Sadri G. "Smoking cessation support in Iran: availability, sources & predictors". *Indian J Med Res*. 2011;133(6):627-32.
158. Sarrafazadegan N, Rabiei K, Alavi M, Abedi H and Zarfeshani S. "How can the results of a qualitative process evaluation be applied in management, improvement and modification of a preventive community trial? The IHHP Study". *Archives of Public Health* 2011; 69:9.

159. Najafpour Boushehri S, Mohamad Yiusof R, NasirMohamad Taib I, Yassin Z, Sarrafadegan N, et al. "Effects of antioxidant vitamins (C, E, Beta-Carotene) supplementation on serum 8-iso-prostaglandin PGF2a in male subjects with risk factors for cardiovascular diseases". Middle-East Journal of Scientific Research 2011; 10(5):577-580.
160. Sadeghi M, Roohafza H, Afshar H, Rajabi F, Ramzani MA, Shemirani H, Sarrafadegan N. "Relationship between depression and apolipoproteins A and B: a case-control study". CLINICS 2011; 66(1):113-117.
161. Rajabizadeh G, Ramezani MA, Roohafza H, Pourdanghan N, Khosravi A, Rabiei K, Sarrafzadegan N, Toghianifar N, Zarfeshani S. "Association between cigarette smoking and socio-emographics, lifestyle and mental health factors in a sampled Iranian population". Southeast Asian J Trop Med Public Health, 2011; 42(4):977-87.
162. Shirani Sh, Gharipour M, Khosravi A, Kelishadi R, Habibi H.R, Abdalvand A, Sarrafadegan N. "Gender differences in the prevalence of hypertension in a representative sample of iranian population: The Isfahan Healthy Heart Program". Acta Biomed 2011; 82: 223-229.
163. Toghianifar N, Najafian J, Pooya A, Rabiei K, Eshrati B, Anaraki J and Sarrafadegan N. "Association of smoking status with quality of life in a cross-sectional population-based Sample of Iranian adults: Isfahan Healthy Heart Program". Asia Pac J Public Health 2011; 24(5):786-94.
164. Sadeghi M, Aghdak P, Motamedi N, Tavassoli A, Kelishadi R, Sarrafadegan N. "Do intervention strategies of women healthy heart project (WHHP) impact on differently on working and housewives?". ARYA Atheroscler, 2011; 6(4):129-35.
165. Mohammadifard N, Sarrafadegan N, Nouri F, Sajadi F, Alikhasi H, Maghroon M, Kelishadi R, Iraj F, Rahmati MR. "Using factor analysis to identify dietary patterns in Iranian adults: Isfahan Healthy Heart Program". International Journal of Public Health 2011; 57(1):235-241.
166. Akhlaghi A, Shirani Sh, ZiaieN, Pirhaji O, Yaran M, Shahverdi G, Sarrafadegan N, Khosravi A, Khosravi E. "Cytochrome P450 2C19 polymorphism in Iranian patients with coronary artery disease". ARYA Atherosclerosis Journal, 2011; 7(3):1-6.
167. Roohafza H, Shahn timer M, Zolfaghari B, , Tavassoli A, Sadeghi M, Toloei HR, Sadri G, Sarrafadegan N. "Stress level and smoking status in central Iran: Isfahan Healthy Heart Program". ARYA Atherosclerosis Journal, 2011; 6(4): 144-148.
168. Sadeghi M, Pourmoghaddas Z, Alisaeydi A, Boshtam M, Yazdekhashti S, Sarrafadegan N. "Is there any relation between Circulating Endothelial-Leukocyte adhesion molecule -1 and extent of coronary artery involvements in men with angina pectoris?". Iranian Heart Journal 2011;12(4):37-42.
169. Mazaheri Sh, Sadeghi M, Sarrafadegan N, Sanei H, Hekmatnia A, Tavakoli B. "Correlation between body fat distribution, plasma lipids and apolipoproteins with the severity of coronary involvement in patients with stable angina". ARYA Atherosclerosis Journal, 2011; 6(4):142-146.
170. Sadri Gh, Sadeghi M, Sarrafadegan N, Roohafza H, Yazdani H, Boshtam M, et al. "The relation between hematologic variables and metabolic syndrome". Iranian Heart Journal 2011; 12(3):40-6.
171. Haghjoo S, Haghdoost F, Keyhanian K, Samety AA, Loghmani P, Rafiee L, Sarrafadegan N, Asgari S. "Association between Heme Oxygenase-1 gene promoter polymorphisms and metabolic syndrome in Iranians". Clinical Biochemistry 2011;44(13): S302-S303.

172. Basati G, Ziaaldin SS, Movahedian A, Pourfarzam M, Sarrafzadegan N. "The association of plasma leptin and homocysteine levels with the severity of coronary artery disease". *Clinical Biochemistry* 2011;44(13): S1-S1.
173. Roohafza H, Sarrafzadegan N, Sadeghi S, Talaei M, Talakar M, Mahvash M. "The effectiveness of stress management intervention in a community-based program: Isfahan healthy heart program". *ARYA Atherosclerosis Journal*, 2012; 7(4):176-183.
174. Sadeghi M, Sarrafzadegan N, Shahabi J, Naghnaian M, Hedayat P. "The five-year trend of coronary artery diseases based on angiography results in central part of Iran". *Iranian Heart Journal*, 2012; 13(2):12-19.
175. Talaei M, Sadeghi M, Marshall T, Thomas GN, Kabiri P, Hoseini S, Sarrafzadegan N. "Impact of metabolic syndrome on ischemic heart disease - A prospective cohort study in an Iranian adult population: Isfahan cohort study". *Nutr Metab Cardiovasc Dis*. 2012; 22(5):434-41.
176. Sarrafzadegan N, Gharipour M, Sadeghi S, Khosravi A, Tavassoli AA. "Metabolic syndrome in Iranian elderly". *ARYA Atherosclerosis Journal*, 2012; 7(4):157-161.
177. Javanmard SH, Keyhanian K, Loghmani P, Samety AA, Haghdoost F, Rafiei L, Talaei M, Asgari S, Jazi MH, Sarrafzadegan N. "Association between heme oxygenase-1 gene promoter polymorphisms and metabolic syndrome in Iranians". *Mol Biol Rep*. 2012;39(3):3355-60.
178. Talaei M, Thomas GN, Marshall T, Sadeghi M, Iranipour R, Oveisgharan Sh, Sarrafzadegan N. "Appropriate cut-off values of waist circumference to predict cardiovascular outcomes: 7-year follow-up in an Iranian population". *Intern Med*. 2012; 51(2):139-46.
179. Khosravi A, Toghianifar N, Sarrafzadegan N, Gharipour M, Azadbakht L. "Salt intake, obesity, and pre-hypertension among Iranian adults: A cross-sectional study". *Pakistan Journal of Medical Sciences* 2012; 28(2):297-302.
180. Kabir A, Sarrafzadegan N, Amini A, Safi Aryan R, Habibi Kerahroodi F, Rabiei K, Taghipour HR, Moghimi M. "Impact of Cardiac Rehabilitation on Metabolic Syndrome in Iranian Patients with Coronary Heart Disease: The Role of Obesity". *Rehabilitation Nursing* 2012; 37(2):66-73.
181. Pourmoghaddas Z, Sadeghi M, Hekmatnia A, et al. "Different measurements of the obesity, adiponectin and coronary heart disease". *J Res Med Sci*.2012; 17(Spec 2): S218-S222
182. Sarrafzadegan N, Talaei M, Kelishadi R, Toghianifar N, Sadeghi M, Oveisgharan S, Kabiri P, Tavassoli A, Mohammadifard N, Thomas GN, Marshall T. "The influence of gender and place of residence on cardiovascular diseases and their risk factors. The Isfahan Cohort Study". *Saudi Med J*. 2012; 33(5):533-40.
183. Roohafza H, Sadeghi M, Talaei M, Pourmoghaddas Z, Sarrafzadegan N. "Psychological Status and Quality of Life in relation to the Metabolic Syndrome: Isfahan Cohort Study". *International Journal of Endocrinology* 2012. doi: 10.1155/2012/380902.
184. Masoudkabir F, Toghianifar N, Talaie M, Sadeghi M, Sarrafzadegan N, Mohammadifard N, Marshall T, Thomas G.N. "Socioeconomic status and incident cardiovascular disease in a developing country: findings from the Isfahan cohort study (ICS)". *Int J. Public Health* 2012;57(3):561-8.
185. Khosravi AR, Kelishadi R, Sarrafzadegan N, Boshtam M, Nouri Zarfeshani S, Esmailzadeh A. "Impact of a community-based lifestyle intervention program on blood pressure and salt intake of normotensive adult population in a developing country". *J Res Med Sci*. 2012; 17(3):235-241.

186. Sadeghi M, Golabchi A, Haghani P, Gharipour M, Naderi GA, Sarrafazadegan N. "Can anti-streptokinase antibody predict myocardial infarction outcomes after streptokinase treatment?". *J Pak Med Assoc*. 2012; 62(3) Suppl 1:S31-4.
187. Mohammadifard N, Fahimi S, Khosravi A, Pouraram H, Sajedinejad S, Pharoah P, Malekzadeh R, Sarrafazadegan N. "Advocacy strategies and action plans for reducing salt intake in Iran". *Arch Iran Med*. 2012; 15(5):320-4.
188. Khosravi-Boroujeni H, Sarrafazadegan N, Mohammadifard N, Alikhassi H, Sajjadi F, Asgari S, Esmailzadeh A. "Consumption of sugar-sweetened beverages in relation to the metabolic syndrome among Iranian adults". *Obes Facts* 2012; 5(4):527-37.
189. Sarrafazadegan N, Sadeghi M, Khademi F, Ramezani MA, Hashemi Jazi M. "The relation of cardiovascular risk factors and Electrocardiogram (EKG) changes". *ARYA Atherosclerosis Journal* 2012, 7(Suppl): S94-S98.
190. Sarrafazadegan N, Sadeghi M, Ghaffaripasand F, Alisaieidi A, Sanei H, Zakeri H, Rastegar T, Amiri A, Dehghankhalili M. "Interleukin-6 and E-selectin in acute coronary syndromes and stable angina pectoris. A comparative study. *Herz*. 2012;37(8):926-30.
191. Khosravi A, Kelishadi R, Sarrafazadegan N, Boshtam M, Nouri F, Zarfeshani S, Esmailzadeh A. "Impact of a community-based lifestyle intervention program on blood pressure and salt intake of normotensive adult population in a developing country". *J Res Med Sci*. 2012; 17(3):235-41.
192. Sabzghabae AM, Dianatkah M, Sarrafazadegan N, Asgary S, Ghannadi A. "Clinical evaluation of *Nigella sativa* seeds for the treatment of hyperlipidemia: a randomized, placebo controlled clinical trial". *Med Arh*. 2012; 66(3):198-200.
193. Aghababaei I, Sadeghi M, Talaei M, Rabiei K, Sarrafazadegan N. "Is prehypertension a risk factors for cardiovascular diseases among Iranian women?" *J Res Med Sci*. 2012; 17(10): 947-951.
194. Nezarat N, Sadeghi M, Rabiei K, Afsharmoghaddam N, Sarrafazadegan N, Setareh M, et al. "The Effect of body fat distribution on coronary and carotid atherosclerosis (An autopsy Study)". *J Res Med Sci* 2012; 17(Spec 1):S125-S130.
195. Noohi F, Sarrafazadegan N, Khosravi A, Andalib E. "The first Iranian recommendations on prevention, evaluation and management of high blood pressure". *ARYA Atherosclerosis Journal*, 2012; 8(3):9.
196. Ghashghaei FE, Sadeghi M, Rabiei K, Roohafza H, Sarrafazadegan N. "Gender differences in risk factors of obese patients after cardiac rehabilitation program". *Iran J Nurs Midwifery Res*. 2012;17(5):381-5.
197. Kelishadi R, Mohammadifard N, Sarrafazadegan N, Nouri F, et. al. "The effects of a comprehensive community trial on cardiometabolic risk factors in adolescents: Isfahan Healthy Heart Program". *ARYA Atheroscler*. 2012;7(4):184-90.
198. Aghababaei I, Sadeghi M, Talaei M, Rabiei K, Sarrafazadegan N. "Do hypertension and prehypertension count as cardiovascular risk factors among women in an Iranian society". *International Journal of Cardiology* 2012 ;155, Supplement 1:S2-S2
199. Sarrafazadegan N, Kelishadi R, Siavash M, Sadri G, Malekafzali H, Pourmoghaddas M, Shirani S, Boshtam M, Asgary S, Mohammadifard N, Bahonar A, Eshrati B, Ghamsari F. "How does the impact of a community trial on cardio-metabolic risk factors differ in terms of gender and living area? Findings from the Isfahan healthy heart program". *J Res Med Sci*. 2012;17(8):732-40.

200. Boshtam M, Ramezani MA, Naderi G, Sarrafazadegan N. "Is Fried Ewald formula a good estimation for low density lipoprotein level in Iranian population?". *J Res Med Sci*. 2012; 17(6):519-22.
201. Ghashghaei FE, Sadeghi M, Mostafavi S, Heidari H, Sarrafazadegan N. "The effect of the cardiac rehabilitation program on obese and non-obese females with coronary heart disease". *Adv Biomed Res*. 2012; 1:17. doi: 10.4103/2277-9175.96077.
202. Khosravi AR, Rowzati M, Gharipour M, Fesharaki MG, Shirani S, Shahrokhi S, Jozan M, Khosravi E, Khosravi Z, Sarrafazadegan N. "Hypertension control in industrial employees: findings from SHIMSCO study". *ARYA Atheroscler* 2012; 7(4):191-6.
203. Khosravi-Boroujeni H, Mohammadifard N, Sarrafazadegan N, Sajjadi F, Maghroun M, Khosravi A, Alikhasi H, Rafieian M, Azadbakht L. "Potato consumption and cardiovascular disease risk factors among Iranian population". *Int J Food Sci Nutr*. 2012; 63(8):913-20.
204. Abolhassani S, Irani MD, Sarrafazadegan N, Rabiei K, Shahrokhi S, Pourmoghaddas Z, Mohammadifard N, Roohafza H, Asgary S, Moattar F. "Barriers and facilitators of weight management in overweight and obese people: Qualitative findings of TABASSOM project". *Iran J Nurs Midwifery Res*. 2012; 17(3):205-10.
205. Khosravi Boroujeni H, Sarrafazadegan N, Mohammadifard N, Sajjadi F, Asgari S, Maghroun M, Alikhasi H, Esmailzaded A. "The relation between dietary intake of vegetable oils and serum lipids and apolipoprotein levels in central Iran". *ARYA Atherosclerosis Journal* 2012; 7(4): 168–175.
206. Garakyaraghi M, Kianjoo M, Mortazavi M, Sarrafazadegan N, Shemirani H, Shahparian M. "The efficacy of pharmaceutical combination of glucose, insulin, potassium, and magnesium along with thrombolytic therapy on the mortality of patients with acute myocardial infarction". *Arya Atherosclerosis Journal* 2012;7(Suppl 5) :S36-S41.
207. Khaledifar A, Bahonar A, Asadilari M, Boshtam M, Gharipour M, Taghdisi MH, Sarrafazadegan N. "Risk factors of cardiovascular diseases in a worker population in Isfahan province (Isfahan Electricity Production and Distribution Company)". *Arya Atherosclerosis Journal* 2012;7(Suppl 5) :S82-87.
208. Shimony A, Grandi SM, Pilote L, Joseph L, O'Loughlin J, Paradis G, Rinfret S, Sarrafazadegan N, Adamjee N, Yadav R, Gamra H, Diodati JG, Eisenberg MJ; for the ZESCA investigators. "Utilization of Evidence-Based Therapy for Acute Coronary Syndrome in High-Income and Low/Middle-Income Countries". *Am J Cardiol*. 2014;113(5):793-7
209. Masoudkabir F, Sarrafazadegan N, Eisenberg MJ. "Effects of opium consumption on cardiometabolic diseases". *Nat Rev Cardiol* 2013;10(12):733-40.
210. Eisenberg MJ, Grandi SM, Gervais A, O'Loughlin J, Paradis G, Rinfret S, Sarrafazadegan N, Sharma S, Lauzon C, Yadav R, Pilote L; ZESCA Investigators. "Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial". *J Am Coll Cardiol* 2013;61(5):524-32.
211. Sadeghi M, Garakyaraghi M, Khosravi M, Taghavi M, Sarrafazadegan N, Roohafza H. "The impacts of cardiac rehabilitation program on echocardiographic parameters in coronary artery disease patients with left ventricular dysfunction". *Cardiol Res Pract*. 2013. <http://dx.doi.org/10.1155/2013/201713>.
212. Mohammadifard N, Nazem M, Sarrafazadegan N, Nouri F, Sajjadi F, Maghroun M, Alikhasi H. "Body mass index, waist-circumference and cardiovascular disease risk factors in Iranian adults: Isfahan Healthy Heart Program". *J Health Popul Nutr*. 2013;31(3):388-97.

213. Gharipour M, Ramezani MA, Sadeghi M, Khosravi A, Masjedi M, Khosravi-Boroujeni H, Rafieian-Kopaei M, Sarrafazadegan N. "Sex based levels of C-reactive protein and white blood cell count in subjects with metabolic syndrome: Isfahan Healthy Heart Program". *J Res Med Sci*. 2013;18(6):467-72.
214. Khaledifar A, Gharipour M, Bahonar A, Sarrafazadegan N, Khosravi A. "Association between salt intake and Albuminuria in normotensive and hypertensive individuals. *Int J Hypertens*. 2013. doi: 10.1155/2013/523682.
215. Sadeghi M, Pourmoghaddas Z, Hekmatnia A, Sanei H, Tavakoli B, Tchernof A, Roohafza H, Sarrafazadegan N. "Association of apolipoprotein B, apolipoprotein A, and the its ratio with body fat distribution". *J Res Med Sci*. 2013;18(4):326-9.
216. Yazdekhasti N, Mohammadifard N, Sarrafzadegan N, Mozaffarian D, Nazem M, Taheri M. "The relationship between nut consumption and blood pressure in an Iranian adult population: Isfahan Healthy Heart Program". *Nutr Metab Cardiovasc Dis*. 2013;23(10):929-36.
217. Haghghatdoost F, Sarrafazadegan N, Mohammadifard N, Sajjadi F, Maghroun M, Boshtam M, Alikhasi H, Azadbakht L. "Healthy eating index and cardiovascular risk factors among Iranians". *J Am Coll Nutr*. 2013;32(2):111-21.
218. Sadeghi M, Shiri M, Roohafza H, Rakhshani F, Sepanlou S, Sarrafazadegan N. "Developing an appropriate model for self-care of hypertensive patients: first experience from EM RO". *ARYA Atheroscler*. 2013;9(4):232-40.
219. Khosravi-Boroujeni H, Sarrafazadegan N, Mohammadifard N, Sajjadi F, Maghroun M, Asgari S, Rafieian-Kopaei M, Azadbakht L. "White rice consumption and CVD risk factors among Iranian population". *J Health Popul Nutr*. 2013;31(2):252-61.
220. Alavi M, Irajpour A, Giles T, Rabiei K, Sarrafazadegan N. "Barriers to education in cardiac rehabilitation within an Iranian society: a qualitative descriptive study". *Contemp Nurse*. 2013;44(2):204-14.
221. Talaei M, Sadeghi M, Marshall T, Thomas GN, Iranipour R, Nazarat N, Sarrafazadegan N. "Anthropometric indices predicting incident type 2 diabetes in an Iranian population: the Isfahan Cohort Study". *Diabetes Metab*. 2013;39(5):424-31.
222. Mohammadifard N, Sarrafazadegan N, Ghassemi GR, Nouri F, Pashmi R. "Alteration in unhealthy nutrition behaviors in adolescents through community intervention: Isfahan Healthy Heart Program". *ARYA Atheroscler* 2013;9(1):89-97.
223. Shokouh P, Joharimoghadam A, Roohafza H, Sadeghi M, Golabchi A, Boshtam M, Sarrafazadegan N. "Effects of Pioglitazone on asymmetric dimethylarginine and components of the metabolic syndrome in nondiabetic patients (EPICAMP Study): A double-blind, randomized clinical trial". *PPAR Res*. 2013;2013:358074. doi: 10.1155/2013/358074.
224. Gharipour M, Khosravi A, Sadeghi M, Roohafza H, Hashemi M, Sarrafazadegan N. "Socioeconomic characteristics and controlled hypertension: Evidence from Isfahan Healthy Heart Program". *ARYA Atheroscler*. 2013;9(1):77-81.
225. Sarrafazadegan N, Gharipour M, Sadeghi M, Nouri F, Asgary S, Zarfeshani S. "Differences in the prevalence of metabolic syndrome in boys and girls based on various definitions". *ARYA Atheroscler*. 2013;9(1):70-6.
226. Sarrafazadegan N, Rabiei K, Nouri F, Mohammadifard N, Moattar F, Roohafza H, Haghjooy Javanmard S, Zarfeshani S, Pourmoghaddas M. "Parental perceptions of weight status of their children". *ARYA Atheroscler*. 2013;9(1):61-9.

227. Ahmadi A, Gharipour M, Nouri F, Sarrafazadegan N. “Metabolic syndrome in Iranian youths: a population-based study on junior and high schools students in rural and urban areas”. *J Diabetes Res*. 2013;738485.
228. Talaei M, Rabiei K, Talaei Z, Amiri N, Zolfaghari B, Kabiri P, Sarrafazadegan N. “Physical activity, sex, and socioeconomic status: A population based study”. *ARYA Atheroscler*. 2013;9(1):51-60.
229. Roohafza H, Sadeghi M, Shahn timer M, Shokouh P, Teimori S, Amirpour A, Sarrafazadegan N. “Social norms of cigarette and hookah smokers in Iranian universities”. *ARYA Atheroscler*. 2013;9(1):45-50.
230. Gharipour M, Sarrafazadegan N, Sadeghi M, Andalib E, Talaie M, Shafie D, Aghababaie E. “Predictors of metabolic syndrome in the Iranian population: waist circumference, body mass index, or waist to hip ratio?”. *Cholesterol*. 2013;2013:198384. doi: 10.1155/2013/198384
231. Mohammadifard N, Toghianifar N, Sajjadi F, Alikhasi H, Kelishadi R, Maghroun M, Esmaeili M, Ehteshami S, Tabaie H, Sarrafazadegan N. “Improvement of dietary oil consumption following a community trial in a developing country: The role of translational research in health promotion”. *ARYA Atheroscler*. 2013;9(1):29-37.
232. Keyhani D, Kargarfard M, Sarrafazadegan N, Sadeghi M. “Autonomic function change following a supervised exercise program in patients with congestive heart failure”. *ARYA Atheroscler*. 2013;9(2):150-6.
233. Talaei M, Mohammadifard N, Khaje MR, Sarrafazadegan N, Sajjadi F, Alikhasi H, Maghroun M, Irajii F, Ehteshami S. “Healthy bread initiative: methods, findings, and theories--Isfahan Healthy Heart Program”. *J Health Popul Nutr*. 2013;31(1):49-57.
234. Sali R, Roohafza H, Sadeghi M, Andalib E, Shavandi H, Sarrafazadegan N. “Validation of the revised stressful life event questionnaire using a hybrid model of genetic algorithm and artificial neural networks”. *Comput Math Methods Med*. 2013;2013:601640. doi: 10.1155/2013/601640.
235. Haghghatdoost F, Sarrafazadegan N, Khosravi A, Noori F, Boshtam M, Mohammadifard N, Abdollihi Z, Azadbakht L. “Is the association between salt intake and blood pressure mediated by body mass index and central adiposity?”. *Arch Iran Med*. 2013;16(3):167-71.
236. Sarrafazadegan N, Khosravi-Boroujeni H, Esmailzadeh A, Sadeghi M, Rafieian-Kopaei M, Asgary S. “The association between hypertriglyceridemic waist phenotype, menopause, and cardiovascular risk factors”. *Arch Iran Med*. 2013;16(3):161-6.
237. Roohafza H, Talaei M, Sadeghi M, Haghani P, Shokouh P, Sarrafazadegan N. “Opium decreases the age at myocardial infarction and sudden cardiac death: a long- and short-term outcome evaluation”. *Arch Iran Med*. 2013;16(3):154-60.
238. Sadeghi M, Pourmoghaddas Z, Hekmatnia A, Sanei H, Tavakoli B, Tchernof A, Roohafza H, Sarrafazadegan N. “Abdominal fat distribution and serum lipids in patients with and without coronary heart disease”. *Arch Iran Med*. 2013; 16(3):149-53.
239. Roohafza H, Sarrafazadegan N, Sadeghi M, Rafieian-Kopaei M, Sajjadi F, Khosravi-Boroujeni H. “The association between stress levels and food consumption among Iranian population”. *Arch Iran Med*. 2013;16(3):145-8.
240. Talaei M, Sarrafazadegan N, Sadeghi M, Oveisgharan S, Marshall T, Thomas GN, Iranipour R. “Incidence of cardiovascular diseases in an Iranian population: the Isfahan Cohort Study”. *Arch Iran Med*. 2013;16(3):138-44.

241. Askari G, Yazdekhashti N, Mohammadifard N, Sarrafazadegan N, Bahonar A, Badiei M, Sajjadi F, Taheri M. "The relationship between nut consumption and lipid profile among the Iranian adult population; Isfahan Healthy Heart Program". *Eur J Clin Nutr.* 2013;67(4):385-9.
242. Sarrafazadegan N, Kelishadi R, Sadri G, Malekafzali H, Pourmoghaddas M, Heidari K, Shirani S, Bahonar A, Boshtam M, Asgary S, Mohammadifard N, Sadeghi M, Eshrati B, Hadipour E, Esmailzadeh A, O'Loughlin J. "Outcomes of a comprehensive healthy lifestyle program on cardiometabolic risk factors in a developing country: the Isfahan healthy heart program." *Arch of Iran Med.*, 2013; 16(1):4-11.
243. Pourfarzam M, Movahedian A, Sarrafazadegan N, Basati Gh, Samsamshariat S.Z. "Association between Plasma Myeloperoxidase and Free 3-Nitrotyrosine Levels in Patients with Coronary Artery Disease". *International Journal of Clinical Medicine*, 2013;4:158-164.
244. Sadeghi M, Ghashghaei FE, Rabiei K, Golabchi A, Noori F, Baboli MT, Sarrafazadegan N. "Does significant weight reduction in men with coronary artery disease manage risk factors after cardiac rehabilitation program?". *J Res Med Sci.* 2013; 18(11):956-960.
245. Yazdekhashti N, Mohammadifard N, Sarrafazadegan N, Mozaffarian D, Nazem M, Taheri M. "The relationship between nut consumption and blood pressure in an Iranian adult population: Isfahan Healthy Heart Program". *Nutrition, Metabolism and Cardiovascular Diseases* 2013; 23(10):929 – 936.
246. Gharipour M, Sadeghi M, Mansourian M, Andalib E, Talaie M, Mohammadifard N, Sarrafazadegan N. "Correlation of circulating inflammatory markers, ghrelin, adiponectin with obesity indices in subjects with metabolic syndrome". *Pakistan Journal of Medical Sciences* 2013; 29(1):264-268.
247. Khosravi AR, Raoufi A, Pourmoghadas M, Paydari N, Gharipour M, Namdari M, Khaledifar A, Khosravi M, Bahonar A, Ostovan M, Hassanzadeh M.E, Sarrafazadegan N. "Late clinical events of drug eluting versus bare metal stenting; OPCES' ancillary study". *Pakistan Journal of Medical Sciences* 2013; 29(1):258-263.
248. Khosravi A, Noohi F, Andalib E, Sadeghiyan S, Peighambari M, Sarrafazadegan N. "Management of high blood pressure: The first Iranian high blood pressure guideline (summary)". *Iranian Heart Journal*, 2013; 14(1):27-35.
249. Sarrafazadegan N, Sadeghi M, Gharipour M, Talaie M, Shafie D, Aghababaie E. "Left Ventricular Diastolic Function in Subjects with Metabolic Syndrome: Isfahan Cohort Study". *Iranian Heart Journal*, 2013; 13(4):63-77.
250. Arabzadeh S, Sadeghi M, Rabiei K, Sarrafazadegan N. "Factors affecting uncontrolled hypertension in an Iranian population". *Iranian Heart Journal* 2013; 14(3).
251. Talaie M, Sadeghi M, Mohammadifard N, Shokouh P, Oveisgharan S, Sarrafazadegan N. "Incident hypertension and its predictors: the Isfahan Cohort Study". *J Hypertens* 2014; 32(1):30-8.
252. Soltani R, Hakimi M, Asgary S, Ghanadian SM, Keshvari M, Sarrafazadegan N. "Evaluation of the effects of Vaccinium arctostaphylos L. fruit extract on serum lipids and hs-CRP levels and oxidative stress in adult patients with hyperlipidemia: a randomized, double-blind, placebo-controlled clinical trial". *Evidence-Based Complementary and Alternative Medicine* 2014; DOI: 10.1155/2014/217451
253. Roohafza H, Sadeghi M, Naghnaeian M, Shokouh P, Ahmadi A, Sarrafazadegan N. "Relationship between metabolic syndrome and its components with psychological distress". *International Journal of Endocrinology* 2014. <http://dx.doi.org/10.1155/2014/203463>

254. Rafiee L, Abedini M, Haghjooy Javanmard Sh, Sarrafazadegan N, Mansourian M. "Association of GSTT1 and GSTM1 polymorphisms with blood pressure: A Bayesian modeling of continuous data". *J Res Med Sci*.2014; 19(3):200-204.
255. Sarrafazadegan N, Rabiei K, Abedi H, Kelishadi R, Fereydoun Mohaseli Kh, Alavi M, Roohafza H. "Indicators Developed to Evaluate the International Framework Convention on Tobacco Control in Iran; A Grounded Theory Study". *Iran J Med Sci*. 2014; 39(2):213-217.
256. Sarrafazadegan N, Rabiei K, Wong F, Roohafza H, Zarfeshani S, Noori F, Grainger Gasser A. "The sustainability of interventions of a community-based trial on children and adolescents' healthy lifestyle". *ARYA Atherosclerosis* 2014;10(2):107-117.
257. Gharipour M, Sadeghi M, Dianatkah M, Bidmeshgi Sh, Ahmadi A, Tahri M, Sarrafazadegan N. "The Cut-Off Values of Anthropometric Indices for Identifying Subjects at Risk for Metabolic Syndrome in Iranian Elderly Men". *Journal of Obesity* 2014.
258. Arabzadeh S, Sadeghi M, Rabiei K, Sarrafazadegan N, Taheri L, Golshahi A. "Determinants of uncontrolled hypertension in an Iranian population". *ARYA Atherosclerosis* 2014;10(1):25-31.
259. Sarrafazadegan N, Rabiei K, Fereydoun Mohaseli Kh, Manzouri L, Roohafza H, Kelishadi R, Abedi H, Azaripour Masooleh H, Alavi M, Heidari Gh. "Do Iranian tobacco growers support the World Health Organization framework convention on tobacco control?". *Journal of Education and Health Promotion* 2014;3(1):32.
260. Dianatkah M, Rahgozar M, Talaei M, Karimloua M, Sadeghi M, Oveisgharan S, Sarrafazadegan N. "Comparison of competing risks models based on cumulative incidence function in analyzing time to cardiovascular diseases". *ARYA Atherosclerosis* 2014;10(1):6-12.
261. Ahmadi A, Gharipour M, Nouri F, Kelishadi R, Sadeghi M, Sarrafazadegan N. "Association between adolescence obesity and metabolic syndrome: Evidence from Isfahan Healthy Heart Program". *Indian Journal of Endocrinology and Metabolism* 2014;18(4):569-573.
262. Haghghatdoost F, Sarrafazadegan N, Mohammadifard N, Asgary S, Boshtam M, Azadbakht L. "Assessing body shape index as a risk predictor for cardiovascular diseases and metabolic syndrome among Iranian adults". *Nutrition* 2014;30(6):636-44.
263. Basati Gh, Emami Razavi A, Abdi S, Sarrafazadegan N. "The importance of adipokines in relation to the inflammatory enzyme, myeloperoxidase in patients with coronary artery disease". *Acta Medica Iranica* 2014.
264. Sadeghi M, Khosravi-Boroujeni H, Sarrafazadegan N, Asgary S, Roohafza H, Gharipour M, Sajjadi F, Khaledi S, Rafieian-kopaei M. "Cheese consumption in relation to cardiovascular risk factors among Iranian adults- IHHP Study". *Nutrition Research and Practice* 2014;8(3):336-41.
265. Sadeghi M, Garakyaraghi M, Taghavi M, Khosravi M, Sarrafazadegan N, Roohafza H. "The impacts of cardiac rehabilitation program on exercise capacity, quality of life, and functional status of coronary artery disease patients with left ventricular dysfunction". *Rehabilitation Nursing* 2015;40(5):305-309
266. Toghianifar N, Sarrafazadegan N, Gharipour M, Rabiei K, Najafian J. "Comparison of quality of life scores between cigarette and hookah smokers: findings from Isfahan Healthy Heart Program (IHHP)". *Advances in Epidemiology* 2014.
267. Mohammadian-Hafshejani A, Sarrafazadegan N, Hosseini Sh, Baradaran H, Roohafza H, Sadeghi M, Asadi-Lari M. "Seasonal pattern in admissions and mortality from acute

- myocardial infarction in elderly patients in Isfahan, Iran". *ARYA Atherosclerosis* 2014; 10(1):46-54.
268. Gee M, Campbell N, Sarrafazadegan N, Jafar T, Khalsa T, Mangat B, Poulter N, Prabhakaran D, Sonkodi S, Whelton P, Woodward M, Zhang XH. "Standards for the uniform reporting of hypertension in adults using population survey data: Recommendations from the World Hypertension League Expert Committee". *Journal of Clinical Hypertension* 2014;16(11):773-81.
269. Turk-Adawi K, Sarrafazadegan N, L. Grace Sh. "Global availability of cardiac rehabilitation". *Nat Rev Cardiol* 2014;98:1-11.
270. Alfieri O, Mayosi BM, Park SJ, Sarrafazadegan N, Virmani R. "Exploring unknowns in cardiology". *Nat Rev Cardiol* 2014; 11(11):664-670.
271. Sarrafazadegan N, Talaei M, Sadeghi M, Mohammadifard N, Taheri M, Lotfizadeh M, Esmailzadeh A, Khosravi-Boroujeni H. "Determinants of weight change in a longitudinal study of Iranian adults: Isfahan Cohort Study". *Arch Iran Med.* 2014; 17(8):539-44.
272. Samsam Shariat S.Z, Bolhasani M, Sarrafazadegan N, Najafi S, Asgary S. "Evaluation of relationship between blood Peroxidases activity and Visfatin levels in metabolic syndrome patients". *ARYA Atherosclerosis Journal* 2014; 10(4):218-226.
273. Roohafza H, Kabir A, Sadeghi M, Shokouh P, Aalaei-Andabili H, Mehrabi Y, Sarrafazadegan N. "Effect of psychological distress on weight concern and weight control behaviors." *Arch Iran Med.* 2014;17(9):608-12
274. Roohafza H, Shokouh P, Sadeghi M, Alikhassy Z, Sarrafazadegan N. "A possible role for pioglitazone in the management of depressive symptoms in metabolic syndrome patients (EPICAMP study) -A double blind, randomized clinical trial". *International Scholarly Research Notices* 2014.
275. Basati G1, Razavi AE, Abdi S, Sarrafedegan N. "The association of plasma leptin, homocysteine and nitric oxide levels with the presence and instability of coronary artery disease". *Biomark Med.* 2014;8(3):405-12.
276. Mohammadifard N, Sarrafazadegan N, Paknahade Z, Nouri F. "Inverse association of legume consumption and dyslipidemia: Isfahan Healthy Heart Program". *J Clin Lipidol.* 2014;8(6):584-93.
277. Mohammadifard N, Yazdekhahi N, Stangl GI, Sarrafazadegan N. "Inverse association between the frequency of nut consumption and obesity among Iranian population: Isfahan Healthy Heart Program". *European Journal of Nutrition* 2014.
278. Sadeghi M, Talaei M, Zand I, Oveisgharan Sh, Iranipour R, Esteki Ghashghaei F, Sarrafazadegan N. "Heart rate and cardiovascular events: a nested case-control in Isfahan Cohort Study". *Arch Iran Med* 2014; 17(9):633-7.
279. Toghyanifar N, Sarrafazadegan N. "Women's attitude toward smoking: effect of a community-based intervention on smoking-related social norms". *Int J Evid Based Healthc.* 2014; 12(4):262-6.
280. Asgary S, SamsamShariat SZ, Ghorbani A, Keshvari M, Sahebkar A, Sarrafazadegan N. "Relationship between serum resistin concentrations with metabolic syndrome and its components in an Iranian population". *Diabetes Metab Syndr.* 2014.
281. Roohafza H, Kabir A, Sadeghi M, Shokouh P, Aalaei-Andabili SH, Mehrabi Y, Sarrafazadegan N. "Effect of psychological distress on weight concern and weight control behaviors". *Arch Iran Med.* 2014; 17(9):608-12.

282. Khosravi A, Pourheidar B, Roohafza H, Moezzi M, Mousavi M, Hajjannejad A, Bidram P, Gharipour M, Shirani S, Golshahi J, Boshtam M, Sarrafazadegan N. "Evaluating factors associated with uncontrolled hypertension: Isfahan cohort study, Iran." *ARYA Atherosclerosis* 2014; 10(6):311-8.
283. Sadeghi M, Talaei M, Oveisgharan Sh, Rabiei K, Dianatkhah M, Bahonar A, Sarrafazadegan N. "The cumulative incidence of conventional risk factors of cardiovascular disease and their population attributable risk in an Iranian population: The Isfahan Cohort". *Adv Biomed Res* 2014;3:242.
284. Taheri L, Sadeghi M, Sanei H, Rabiei K, Arabzadeh S, Golshahi J, Afshar H, Sarrafazadegan N. "The relation between occupational exposure to lead and blood pressure among employed normotensive men. *J Res Med Sci.* 2014; 19(6):490-4.
285. Namazi G, Pourfarzam M, Jamshidi Rad S, Movahedian Attar A, Sarrafazadegan N, Sadeghi M, Asa P. "Association of the total cholesterol content of erythrocyte membranes with the severity of disease in stable coronary artery disease". *Cholesterol.* 2014.
286. Shamsipour M, Farzadfar F, Gohari K, Parsaeian M, Amini H, Rabiei K, Hassanvand MS, Navidi I, Fotouhi A, Naddafi K, Sarrafazadegan N, Mansouri A, Mesdaghinia A, Larijani B, Yunesian M.A. "A Framework for exploration and cleaning of environmental data - Tehran air quality data experience". *Arch Iran Med.* 2014;17(12):821-9.
287. Hosseini M , Sarrafazadegan N, Kelishadi R, Monajemi M, Asgary S, Vardanjani HM. "Population-based metabolic syndrome risk score and its determinants: The Isfahan Healthy Heart Program". *J Res Med Sci.* 2014;19(12):1167-74.
288. Golshahi J, Sadeghi M, Mousavi M, Porheidar B, Bidram P, Naderi Boldaji R, Bahonar A, Heidari E, Mahjoor Z, Sarrafazadegan N. "Association between Positive Family History for Hypertension and Salt Sensitivity of Blood Pressure in Normotensive Individuals". *Iranian Heart Journal* 2014, 4(15): 32-37.
289. Soltani R, Gorji A, Asgary S, Sarrafazadegan N, Mansour S. "Evaluation of the effects of *Cornus mas L.* fruit extract on glycemic control and insulin level in type 2 diabetic adult patients: a randomized, double-blind, placebo-controlled clinical trial". *Evidence-Based Complementary and Alternative Medicine* 2014.
290. Roohafza H, Heidari K, Alinia T, Omidi R, Sadeghi M, Andalib E, Ajami A, Sarrafazadegan N. "Smoking motivators are different among cigarette and waterpipe smokers: The results of ITUPP". *Journal of Epidemiology and Global Health* 2014.
291. Roohafza H, Khani A, Sadeghi M, Bahonar A, Sarrafazadegan N. "Health volunteers' knowledge of cardiovascular disease prevention and healthy lifestyle following a community trial: Isfahan healthy heart program". *Journal of Education and Health Promotion.* 2014; 3:59:48-52.
292. Sadeghi M, Talaei M, Parvaresh Rizi E, Dianatkhah M, Oveisgharan S, Sarrafazadegan N. "Determinants of incident prediabetes and type 2 diabetes in a 7-year cohort in a developing country: The IsfahanCohort Study". *J Diabetes.* 2014; 7(5): 633-641
293. Sarrafzadegan N, Gotay C. CVD prevention in 2014: Advances in the prevention of cardiovascular disease. *Nat Rev Cardiol.* 2015 Feb;12(2):71-3
294. Sadeghi M, Talaei M, Parvaresh E, Dianatkhah M, Oveisgharan Sh, Sarrafzadegan N. "Determinants of incident prediabetes and type 2 diabetes in a 7-year cohort in a developing country: The Isfahan Cohort Study". *J Diabetes.* 2015 Sep;7(5):633-41
295. Namazi G, Jamshidi Rad S, Attar AM, Sarrafzadegan N, Sadeghi M, Naderi G, Pourfarzam M. "Increased membrane lipid peroxidation and decreased Na⁺/K⁺-ATPase activity in

- erythrocytes of patients with stable coronary artery disease". *Coron Artery Dis.* 2015 May;26(3):239-44
296. Ostovaneh MR, Poustchi H, Hemming K, Marjani H, Pourshams A, Nateghi A, Majed M, Navabakhsh B, Khoshnia M, Jaafari E, Mohammadifard N, Malekzadeh F, Merat S, Sadeghi M, Naemi M, Etemadi A, Thomas GN, Sarrafzadegan N, Cheng K, Marshall T, Malekzadeh R. "Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial".. *Eur J Prev Cardiol.* 2015 Dec;22(12):1609-17
 297. Mohammadian M, Hosseini S, Sadeghi M, Sarrafzadegan N, Salehiniya H, Roohafza H, " Trends of 28 days case fatality rate after first acute myocardial infarction in Isfahan, Iran, from 2000 to 2009. *ARYA Atherosclerosis.* 2015;11(4):233-43.
 298. Gharipour M, Sarrafzadegan N, Sadeghi M, Khosravi A, Hoseini M, Khosravi-Boroujeni H, Khaledifar A. "The metabolic syndrome and associated lifestyle factors among the Iranian population". *Adv Biomed Res.* 2015;4:84.
 299. Gharipour M, Sadeghi M, Hosseini H, Andalib E, Bakhtiari Boroujeni M, Sarrafzadegan N. "Effect of age on phenotype of metabolic syndrome in developing country". *Adv Biomed Res.* 2015;4:103.
 300. Mohammadifard N, Salehi-Abargouei A, Salas Salvadó J, Guasch Ferre M, Humphries K, Sarrafzadegan N. "The effect of tree nut, peanut and soy nut consumption on blood pressure: a systematic review and meta-analysis of randomized controlled clinical trials". *Am J Clin Nutr.* 2015 May;101(5):966-82.
 301. Khaledifar A, Gharipour M, Bahonar A, Sarrafzadegan N, Khosravi A. Association between dietary salt intake and reservation of renal function in patients with mild hypertension. *ARYA Atheroscler.* 2015 Feb;11(Suppl 1):69-73.
 302. Mohammadifard N, Sajjadi S, Maghroun M, Alikhasi H, Nilforoushzadeh F, Sarrafzadegan N . "Validation of a simplified food frequency questionnaire for the assessment of dietary habits in Iranian adults: Isfahan Healthy Heart Program". *ARYA Atherosclerosis* 2015; 11(2): 139-46.
 303. Basati G, Emami Razavi A, Abdi S, Sarrafzadegan N. "Association between adipokine and myeloperoxidase levels in patients with coronary artery disease". *Acta Med Iran.* 2015; 53(1):25-9.
 304. Kafeshani O, Sarrafzadegan N, Nouri F, Mohammadifard N. Major dietary patterns in Iranian adolescents: Isfahan Healthy Heart Program, Iran. *ARYA Atheroscler.* 2015 Feb;11(Suppl 1):61-8.
 305. Heidari Z, Feizi A, Azadbakht L, Sarrafzadegan N. "Usual Intake Distribution of Vitamins and Prevalence of Inadequacy in a Large Sample of Iranian At-Risk Population: Application of NCI Method". *J Am Coll Nutr.* 2015;9: 1-12.
 306. Gharipour M, Bahonar A, Sarrafzadegan N, Khosravi A, Khaledifar A. Are there any differences in education levels and changes of cardiovascular risk factors among urban and rural population: Isfahan Healthy Heart Program. *J Educ Health Promot.* 2015; 4:24.
 307. Roohafza H, Sadeghi M, Khani A, Afshar H, Sarrafzadegan N, Scheidt C.E. Development and validation of cardiac patient competence questionnaire, Iranian version. *ARYA Atheroscler.* 2015 Jul; 11(4): 220–227.
 308. Gharipour M, Sadeghi M, Talaie M, Sarrafzadegan N. "Anthropometric Indices Predicting Incident Hypertension in an Iranian Population: The Isfahan Cohort Stud". *Journal of Hypertension* 2015;33, Supplement 1: e 394-e394.

309. Dadjou Y, Sadeghi M, Kermani-Alghoraishi M, Talaei M, Yousefy A, Oveisgharan Sh, Sarrafzadegan N. "The Impact of Health-Related Quality of Life on the Incidence of Ischemic Heart Disease and Stroke; A Cohort Study in An Iranian Population". *Acta Cardiologica* 2015.
310. Mohammadian M, Hosseini SH, Salehiniya H, Sadeghi M, Sarrafzadegan N, Roohafza H, Khazaei S, Soltani SH, Sarrafkia A, Mohammadian-Hafshejani A. "Prognostic factors of 28 days survival rate in patients with a first acute myocardialinfarction based on gender in Isfahan, Iran (2000-2009)". *ARYA Atheroscler.* 2015 Nov;11(6):332-40.
311. Roohafza H, Heidari K, Alinia T, Omidi R, Sadeghi M, Andalib E, Ajami A, Sarrafzadegan N. "Smoking motivators are different among cigarette and waterpipe smokers: The results of ITUPP". *J Epidemiol Glob Health* 2015 Sep;5(3):249-58.
312. Khosravi-Boroujeni H, ,Ahmed F , M Sadeghi M, Roohafza H,Talaei M, Dianatkhah M, Pourmogaddas A , Sarrafzadegan N. "Does the impact of metabolic syndrome on cardiovascular events vary by using different definitions?" *BMC Public Health* 2015;15:1313.
313. Heidari Z, Feizi A, Azadbakht L, Sarrafzadegan N. "Minerals intake distributions in a large sample of Iranian at-risk population using the National Cancer Institute method: Do they meet their requirements?". *International Journal for Vitamin and Nutrition Research* 2015.
314. Sarrafzadegan N, Khosravi-Boroujeni H, Lotfizadeh M, Pourmogaddas A, Salehi-Abargouei A. "Magnesium status and the metabolic syndrome: a systematic review and metaanalysis". *Nutrition* 2016;32(4):409-17.
315. Alami Harandi S, Sarrafzadegan N, Sadeghi M, Talaei M, Dianatkhah M, Oveisgharan S, Pourmogaddas A, Salehi A, Sedighifard Z. "Do Cardiometabolic Risk Factors Relative Risks Differ for the Occurrence of Ischemic Heart Disease and Stroke?". *Res Cardiovasc Med.* 2016;5(1):e30619
316. Nouri F, Sarrafzadegan N, Mohammadifard N, Sadeghi M and Mansourian M." Intake of legumes and the risk of cardiovascular disease: frailty modeling of a prospective cohort study in the Iranian middle-aged and older population".*European Journal of Clinical Nutrition.* 2016;70(2):217-21.
317. Oveisgharan S, Ghaemmaghami AB, Bahonar A, Sarrafzadegan N." Case fatality rate and disability of stroke in Isfahan, Iran: Isfahan stroke registry." *Iran J Neurol.* 2016 Jan 5;15(1):9-15.
318. Grace, S L ,Turk-Adawi K, Contractor A., Atrey A , Campbell, N, Derman W , Ghisi, GL, Sarkar B K., Yeo T J., Lopez-Jimenez F., Buckley J, Hu D, Sarrafzadegan, N. "Cardiac rehabilitation delivery model for low-resource settings: An International Council of Cardiovascular Prevention and Rehabilitation consensus statement". *Progress in CVD*2016
319. Namazi G, Asa P , Movahedian A , Sarrafzadegan N, Sadeghi M, Pourfarzam M. Investigation of membrane fatty acid profiles in erythrocytes of patients with stable coronary artery disease. *Journal of Clinical Lipidology* 2016
320. Khosravi A,Ahmadzadeh S,gharipour M,Golshahi J,Sadeghi M,Jozan M,Sarrafzadegan N.Is there any relationship between different phenotypes of metabolic syndrome and cardiovascular mortality rate?. *Advanced Biomed Research* 2016
321. Khosravi A, Gharipour M, Nezafati P, Khosravi Z, Sadeghi M, Khaledifar A, Taheri M, Golshahi J, and Sarrafzadegan N. Pre-hypertension, pre-diabetes or both: Which is best at predicting cardiovascular events over the long term?".*Journal of Human Hypertension* 2016
322. Khosravi-Boroujeni H, Ahmed F, Sarrafzadegan N."Is the Association between Vitamin D and Metabolic Syndrome Independent of Other Micronutrients".*Int J Vitam Nutr Res.* 2016
323. Alizadehsania R, Zangoeia MH,Hosseinib MJ,Habibia J,Khosravi A,Roshanzamir M,Khozeimeh F,Sarrafzadeganf N,Nahavandi S."Coronary artery disease detection using computational intelligence methods". *Knowledge-Based Systems*2016

324. Darabi F, Aghaei M, Movahedian A, Pourmoghadas A, Sarrafazadegan N. "The role of serum Levels of microRNA-21 and matrix metalloproteinase-9 in patients with acute coronary syndrome". *Molecular and Cellular Biochemistry* 2016
325. Darabi F et al. "Association of serum microRNA-21 levels with visfatin, inflammation and acute coronary syndromes". *Heart and Vessels* 2016
326. Grace S L, Turk-Adawi K, Contractor A, Atrey A, Campbell N, Derman W, Melo Ghisi GL, Oldridge N, Sarkar BK, Joo Yeo T, Lopez-Jimenez F, Mendis S, Oh P, Hu D, Sarrafazadegan N. "Cardiac rehabilitation delivery model for low-resource settings". *Heart* 2016.
327. Sarrafazadegan N, Gharipour M, Khosravi A, Sadeghi M. "Metabolic Syndrome and the Risk of Ischemic Stroke". *Journal of Stroke and Cerebrovascular Diseases* 2016
328. Mohammadifard N, Khaledifar A, Khosravi A, Nouri F, Pourmoghadas A, Feizi A, Esmailzadeh A, Sarrafazadegan N. "Dietary sodium and potassium intake and their association with blood pressure in a non-hypertensive Iranian adult population: Isfahan salt study". *Nutrition and Diabetes* 2016

National

329. Sarrafazadegan N, Rafiei M. The percentiles and means of serum lipids and body mass index. *J Amoozesh & Darman* 1993; 17:15-24.
330. Sarrafazadegan N. Investigating and follow up of the myocardial infarction patients. *J Amoozesh & Darman* 1994; 4:63-67.
331. Boshtam M, Dokhani Sh, Sarrafazadegan N. The amount of NaCl and fat in all types of cheese used in Isfahan by chemical analysis. *J of Standard* 1994; 7:18-23.
332. Boshtam M, Sarrafazadegan N. Defining the amount of salt in all types of bread used in Isfahan by chemical analysis. *Teb-o-Tazkie* 1994; 13, 14:23-25.
333. Shadzi Sh, Safaie Y, Sarrafazadegan N. The level of lipoproteins among children aged 3-14 of families with positive history of premature myocardial infarction in Isfahan. *J of Cardiovascular Diseases* 1994;4 (10):601-605.
334. Attari A, Sarrafazadegan N, Ghasemi GH. The stressful events occurring among Isfahan population since 5 years ago. *J Mental Behavior* 1995;2(3):30-37.
335. Sarrafazadegan N, Tavassoli A, Mortazavi SMB, Alikhasi H et al. The knowledge, attitude and practice of Isfahan people concerning the risk factors of cardiovascular diseases. *J of Nabz* 1995; 5 (5):18-23.
336. Sarrafazadegan N, Soleimani B. The relation between height and myocardial infarction. *J of Cardiovascular Diseases* 1995; 5(16):893-896.
337. Sarrafazadegan N, Tavassoli A, Hashemipoor M, Kelishadi R. Defining the blood pressure percentiles of Isfahan population. *J of Isfahan Medical School* 1996;14(43):32-40.
338. Hashemipoor M, Kelishadi R, Sarrafazadegan N. Is measuring serum cholesterol essential in children? *J of Isfahan Medical School* 1996;1(2):63-68.
339. Hashemipoor M, Kelishadi R, Sarrafazadegan N. The level of Serum lipids among children in Isfahan. *J Shaheed Beheshti University of Medical Sciences* 1996;20(3):98-107.
340. Rafiei M, Boshtam M, Sarrafazadegan N. Hydrogenation process and change in fatty acids composition in hydrogenated oils. *J Teb- O- Tazkie* 1997;6 (3):20-25.
341. Tavassoli A, Sarrafazadegan N, et al. The relation between positive family history and hypertension in Isfahan population. *J of Tehran University of Medical Sciences* 1997;55(6):86-93.

342. Hashemipour M, Kelishadi R, Sarrafazadegan N. The prevalence of coronary artery disease risk factors in children aged 2-14 in families with premature myocardial infarction. J of Tehran University of Medical Sciences 1997;55(6):62-66.
343. Sarrafazadegan N, Tavassoli A, Rafiei M, et al. The Prevalence of hyperlipidemia among people over 19 years of age in Isfahan. J Mashhad University of Medical Sciences 1996;39 (53):60-67.
344. Sarrafazadegan N, Mohammadifard N, Rafiei M. The prevalence of high triglyceride & decreased high-density lipoprotein syndrome among people over 20 years of age in Isfahan population. J of Tehran University of Medical Sciences 1998;56 (2):49-56.
345. Maghsoodlou S, Sarrafazadegan N, et al. The effect of cardiac rehabilitation programs on exercise capacity of cardiac patients by the results of exercise stress test. J of Medical Council of Islamic Republic of Iran Tehran University of Medical Sciences 1998; 4:253-59.
346. Najafian J, Boshtam M, Sarrafazadegan N, Rafiei M, et al. The relation between CK-MB/CK activity index and serum magnesium and fibrinogen in myocardial infarction. J of Isfahan University of Med Sciences 1999; 3(4):314-318.
347. Sadeghi K, Sarrafazadegan N, Kargarfar M. The effect of cardiac rehabilitation on type A personality of myocardial infarction patients. Olympic J 1999; 1,2(13):83-95.
348. Sajadi F, Sarrafazadegan N, Alikhasi H, Mohammadifard N, Abdar N. "The prevalence of non-insulin dependent diabetes mellitus in Iran during 1976-1997". The Journal of Uremia University of Medical Sciences 1999; 10(2):129-137.
349. Farhad M, Moazzam E, Faghieh-Imany E. Sarrafazadegan N. "A study of knowledge attitude and practice of general practitioners regarding risk factors of cardiovascular disease". J of Isfahan University of Medical Sciences 1999; 3(4):286-89.
350. Sarrafazadegan N, Mohammadifard N, Soltan-Mohammad-Zadeh MS. "Are the myocardial infarction risk factors the same in survived and dead patients?". Iranian J Public Health 2000; 29(1-4):61-68.
351. Mohammadifard N, Sarrafazadegan N, Jalali, A, Alikhasi H, et al. "Food and nutrient intake among adult of Isfahan, Iran". Iranian J Public Health 2000; 29(1-4):127-137.
352. Sadeghi K, Khalili A, Sarrafazadegan N, Boshtam M. "Studying physical activity in Isfahan population". Iranian J Public Health 2000; 29(1-4):69-76.
353. Mohammadifard N, Mehrabiian F, Sarrafazadegan N. "The Effect of modifying fat diet in pregnant and Lactant women on serum lipids of neonatal and infantile". J of Isfahan Medical Sciences 2001; 5(4):307-13.
354. Golshadi I, Ansari R, Asgary S, Sarrafazadegan N, Boshtam M, et al. "Familiarizing with using herbal extracts in Isfahan province". J of Medicinal Plants 2002; 1(2):21-28.
355. Mohammadi Fard N, Sarrafazadegan N, Sadri Gh, Malek-Afzali H, Baghaei A, et al. "Isfahan Healthy Heart Program: A community based interventional program for cardiovascular disease prevention & control, design, method and primary experiences." J of Isfahan University of Medical Sciences 2002; 7(1):1-8.
356. Mohammadifard N, Sarrafazadegan N, Sajadi F, et al. "Effect of cardiac rehabilitation on serum lipid". J of Medical Council of Islamic Republic of Iran 2002; 20(3):199-205.
357. Boshtam M, Rafiei M, Sarrafazadegan N, et al. "Impact of Vitamin E on Type II Diabetic Patients". Journal of Shahid Sadoughi University of Medical Sciences & Health Services 2003; 10(4):32-40.

358. Rafiei M, Boshtam M, Sarrafazadegan N. "Relation between Calcium & Blood Pressure in Isfahan Population". Journal of Isfahan Medical School 2003; 20(67):57-64.
359. Behradmanesh S, Dehghan H, Tavassoli A, Sarrafazadegan N. "Assessment of cost-effectiveness of several strategies for early diagnosis in patients with acute nontraumatic atypical chest pain and nonconclusive electrocardiogram". Journal of Isfahan Medical School 2003; 20(67):26-32.
360. Rafiei M, Boshtam M, Sarrafazadegan N, et al. "The correlation of 24-hr urinary sodium and potassium with blood pressure in adults of Isfahan city". Journal of Tehran University of Medical Science 2003; 60(5):406-415.
361. Kelishadi R, Sadri GH, Sarrafazadegan N, et al. "Dyslipidemia in adolescents. IHHP-HHPC". The Medical Journal of Semnan University 2003; 4(3-4):167-76.
362. Rafiei M, Boshtam M, Tafazoli Shayan F, Sarrafazadegan N, et al. "Prevalence of smoking in adolescents of Isfahan". J Razi 2004; 15(10):18-26.
363. Mohammadifard N, Sarrafazadegan N, Nouri N, Baghery M. "The effect of passive smoking on acute myocardial infarction and its relationship with fibrinogen and serum lipids". Daneshvar Journal 2004; (51):75-80.
364. Ashrafi F, Noorbakhsh M, Haghghi M, Naderi Gh, Poormoghadas M, Sadeghi M, Sarrafazadegan N. "A study of the relationship between coronary/carotid artery disease & breast vessels calcification". Journal of Isfahan Medical School 2004; 22(74,75):37-43.
365. Mohammadifard N, Sarrafazadegan N, et al. "The effect of passive smoking on serum fibrinogen level". J of Daneshvar 2004; 51:75-80.
366. Kelishadi R, Hashemipour M, Sarrafazadegan N. "Effect of some environmental factors on smoking and the consequences of smoking on major cardiovascular disease (CVD) risk factors in adolescents: Isfahan Healthy Heart Program-Heart Health Promotion from Childhood". Journal of Medical Faculty Guilan University of Medical Sciences 2004; 13(50):74-80.
367. Naderi Gh, Sarrafazadegan N, Boshtam M et al. "The Situation of new risk factors of cardiovascular disease in urban population of Isfahan". Journal of Kerman University of Medical Sciences 2004; 11(1):28-35.
368. Sarrafazadegan N, Baghaie AM, Sadeghi M, Amin Zadeh A. "Factor Analysis of Metabolic Syndrome among Iranian Male Smokers". Iran J Med Sci 2005; 30(2):73-79
369. Bosham M, Rfiei M, Sarrafazadegan N, et al. "The relationship between serum vitamin D level coronary artery disease and the associated risk factors in female carpet weavers". J of Qazvin University of Medical Science 2005; 35:44-52.
370. Eshrati B, Fotoohi A, Madjd-Zadeh SR, Sarrafazadegan N, Rahimi A, Mohammad K. "The effect of using Kalleh-Pache smoking & diabetes on myocardial infarction in Arak district of Iran: An extension of Isfahan healthy heart project". Arak University Rahavard Danesh Journal 2007; 9(4):35-44.
371. Boshtam M, Rafiei M, Sadeghi K, Sarrafazadegan N. "The effect of Vitamin E Supplementation on Mild Hypertension". Behbood J 2007; 1:1-6.
372. Alavi M, Rabiei K, Abedi H, Zarfeshani S, Sarrafazadegan N. "Some concepts of the qualitative evaluation of ac community-based health program". Journal of Isfahan Medical School-special Issue in Health Promotion 2009; 529-539.
373. Rabiei K, Lahijan Zadeh A, Shishe Foroush M, Shirani Sh, Ghaderian M, Zarfeshani S, Sarrafazadegan N. "The change in awareness & perception in Isfahan urban society after the

- first pollution reduction maneuver in the city". Journal of Isfahan Medical School-special Issue in Health Promotion 2009; 476-486.
374. Nazari B, Asgary S, Sarrafadegan N, et al. "Determination of fatty acid profiles in ghee & olive oil with emphasis on trans fatty acids by gas chromatography". Journal of Shahrekord University of Medical Sciences 2009; 10(4):57-63.
 375. Sanei H, Kelishadi R, Sarrafadegan N, et al. "Health Promotion of children of parents with premature cardiovascular disease through education of healthy lifestyle: Isfahan Healthy Heart Program- Heart Health Promotion from childhood". Journal of Isfahan Medical School 2009; 27(94):180-188.
 376. Sarrafadegan N, Alavi M, Rabiei K, Abedi HA, Bahonar A, Zarfeshani S. "Management of an interventional community-based program based on information resulted from process evaluation; Isfahan Healthy Heart Program". Health Information Management 2010; 7(3):303-313.
 377. Roshdi Benam M, Sadeghi M, Sanei H, Mashayekhi R, Taheri Sh, Atapour A, Sarrafadegan N, Rarnezani M A, Akhbari M R, Jafaripour I, Maleki F, Madadi R. "Evaluation of Fat Cell's Size, Number and Their Mediators in Ischemic Heart Disease Patients". Journal of Isfahan Medical School, 2010; 28(107):225-237.
 378. Bahonar A, Shahnám M, Asadi-Lari M, Bashtam M, Gharipour M, Taghdisi M, Sarrafadegan N. "Risk factors of cardiovascular diseases among workers in Isfahan". Iran Occupational Health Journal. 2010; 7(1):1-0.
 379. Shafie D, Sadeghi M, Hashemi M, Heydarpour M, Talaei M, Aghababaei E, Sarrafadegan N. "Evaluation of heart rate recovery & exercise capacity in individuals with & without metabolic syndrome". Journal of Isfahan Medical School 2011; 28(115):1-11.
 380. Sarrafadegan N. "Global reduction in the age of cardiovascular disease occurrence". Zahedan Journal of Research in Medical Sciences 2011; 13(1):2-3.
 381. Jani N, Hasanzadeh Kashtli A, Kabiri P, Sarrafadegan N, Esmailzade A. "10 Year Trend in Nutrition Journal Impact Indexes in the World". Health System Research 2011; 7(1):53-60.
 382. Nourbakhsh S, Sarrafadegan N, Azadbakht L. "Studying the Effect of Soy Milk Consumption on Blood Pressure and Anthropometric Parameters in Overweight and Obesity Girls". Health System Research 2011; 7(1):43-52.
 383. Sadat Rajaei S, Zahedi M, Azadbakht L, Esmailzadeh A, Sarrafadegan N. "Dietary Energy Density Associated with Metabolic Syndrome in Women". Health System Research 2011; 6(4):613-625.
 384. Azadbakht L, Farajian S, Barak F, Mir Aghajani M, Sarrafadegan N, Esmailzadeh A. "The Relationship of Red Meat Intake with Metabolic Syndrome and CRP Plasma Concentration in Women". Health System Research 2011; 6(4):666-675.
 385. Alavi M, Abedi H, Rabiee K, Karimi M, Sarrafadegan N. "Concept of the quality of the educational services in cardiac rehabilitation". Iranian Journal of Nursing Research 2011; 6(20):6-16.
 386. Gharipour M, Akhavan Tabib A, Toghianifar N, Tavassoli A, Gharipour A, Sarrafadegan N. "The pattern of pharmacological treatment in subjects with metabolic syndrome: Findings from Isfahan Healthy Heart Program". Journal of Isfahan Medical School 2011; 29(138):1-9.
 387. Sarrafadegan N, Asgary S, Toghianifar N, Talaei M, Tavassoli A, Boshtam M, Sadeghi M. "Association of Apolipoprotein-A, B and Trans Fatty Acids with Cardiovascular Events: Isfahan Cohort Study". Journal of Isfahan Medical School 2011; 28(124):1967-1977.

388. Sadeghi M, Sanei H, Hekmatnia A, Tavakoli B, Boshtam M, Khark M, Sarrafazadegan N. "Evaluation between fat distribution in abdominal CT scan with some physical and biochemical variable in Ischemic patients: GAAMI Study". Journal of Isfahan Medical School, 2011; 124(28):1-10.
389. Jani N, Hassanzadeh Keshteli A, Kabiri P, Sarrafazadegan N, Esmailzadeh A. "10 Year Trend in Nutrition Journal Impact Indexes in the World". Journal of Health System Research. 2011;1:53-90.
390. Golabchi A, Sarrafazadegan N, Pourmoghadas M, Shamsi I, Kazemi SA. "A syndrome that mimicking acute myocardial infarction: A case report". Journal of Isfahan Medical School 2011;29(140): 651-656.
391. Kazemi SA, Sadeghi M, Hashemi SM, Heidari R, Gharipour M, Golabchi A, Sarrafazadegan N. "Evaluating the relation between metabolic syndrome and its components with low ankle to brachial index in an Iranian population". Journal of Isfahan Medical School 2011;28(122):1724-1732.
392. Saeedi A, Sadeghi M, Saneie H, Ramezani M, Sarrafazadegan N. "The Comparison of serum inflammatory markers E-selection and Interlokin-6 in patient with acute coronary syndrome and stable angina". ISMJ. 2011; 14 (3):151-158.
393. Najafpour Boushehri S, Mohammad Yusofi R, Mohammad Taib MN, Yassin Z, Sarrafazadegan N, Mirzaei K, Yazdekhasti N. "Effect of Vitamin Supplementation on Serum Oxidised Low-Density Lipoprotein Levels in Male Subjects with cardiovascular disease Risk Factors". Iranian Journal of Basic Medical Sciences 2012; 15(4):952-958.
394. Sadeghi M, Aghdak P, Dehghan Naseiri, Gaheri R, Sarrafazadegan N. "Comparison of cardiovascular risk factors and healthy lifestyle housewives and working in central Iran _ Isfahan Healthy Heart Program". Journal of Lorestan University of Medical Sciences 2012;13(4):55-64.
395. Sarrafazadegan N, Rabiei K, Sadeghi M, Gharipour M, et al. "The outcome of secondary prevention interventions in a community based interventional Program: Isfahan Healthy Heart program". Yafteh 2012;14(1):55-68.
396. Mohammadian Hafshejani AB, Baradaran H, Sarrafazadegan N, AsadiLari M, Ramezani A, Hosseini SH, AllahBakhshiHafshejani F. "Predicting Factors of Short-term Survival in Patients with Acute Myocardial Infarction in Isfahan Using a Cox Regression Model". Iranian Journal of Epidemiology 2012; 8(2): 31-36.
397. Mohammadian Hafshejani A, Baradaran Atarmoghaddam HR, Sarrafazadegan N. "Evaluation of short-term survival of patients with acute myocardial infarction and the differences between the sexes in Isfahan and Najaf Abad between (1378-1387)". Razi Journal of Medical Sciences 2012;19(95):26-34.
398. Gharipour M, Kelishadi R, Khosravi A, Shirani Sh, Masjedi M, Sarrafazadegan N. "The impact of a community trial on the pharmacological treatment in the individuals with the metabolic syndrome: findings from the Isfahan Healthy Heart Program, 2001-2007". Arch Med Sci 2012; 6.
399. Sarrafazadegan N, Kelishadi R, Rabiei K, Abedi H, Fereydoun Mohaseli Kh, Azaripour Masooleh H, Alavi M, Heidari Gh, Ghaffari M, O'Loughlin J. "A comprehensive model to evaluate implementation of the world health organization framework convention of tobacco control". Iranian Journal of Nursing and Midwifery Research. 2012; 17(3):244-254.

400. Sadeghi M, Pourmoghaddas Z, Hekmatnia A, Sanei H, Sarrafzadegan N. "Is Subcutaneous Fat Tissue Associated with Coronary Artery Disease?". Iranian Journal of Endocrinology and Metabolism, 2012; 14(2): 150-155.
401. Sarrafzadegan N, Sadeghi M, Paidarei N, Abadi E, Forouzani A, Hashemi M, Talaei M. "Metabolic Syndrome and Structural and Functional Echocardiographic Characteristics: A Case Control Study in Isfahan Cohort Study". Iranian Journal of Endocrinology & Metabolism 2012;13(Suppl.6) :658-665.
402. Mohammadian Hafshejani A, Oveisgharan Sh, Sarrafzadegan N. "The Most Frequent and Fatal Types of Acute Myocardial Infarction in Isfahan, Iran". Journal of Isfahan Medical School, 2013; 30(216):1-4.
403. Heidari Z, Azadbakht L, Feizi A, Sarrafzadegan N, Mohammadifard N. "Assessment of the distribution of usual intake of nutrients and estimating prevalence of intake deficiency and excess in a general over 40-years of age population of central region of Iran: Application of the National Cancer Institute (NCI) method". Journal of Isfahan Medical School, 2013; 31(242):954-972.
404. Sadeghi M, Taheri L, Golshahi J, Rabiei K, Sarrafzadegan N. "Left Ventricular Echocardiographic Variables in Occupational Exposure to Lead". Journal of Isfahan Medical School 2014; 32(297).
405. Hakimi M, Soltani R, Keshvari M, Asgari S, Sarrafzadegan N. "The effects of Vaccinium arctostaphylos on lipid profile in mild hyperlipidemia patients- a randomized clinical trial". Journal of Shahrekord University of Medical Sciences 2014; 16(5): 92-99.
406. Asgari S, Taleghani M, Badiie A, Sarrafzadegan N. "Correlation between serum concentration of lead, mercury and cadmium with coronary artery disease". Journal of Shahrekord University of Medical Sciences 2015; 17(2):1-6.

Under Review Manuscripts:

International and National Peer-Reviewed Journals

1. Sadeghi M, Gharipour M, Sarrafzadegan N, Shafie D, Aghababaie E. "Alteration of maximum heart rate in metabolic syndrome"Acta Iranica.
2. Gharipour M, Sadeghi M, Ghassemi Gh, Jozan M, Bakhtiari boroujeni M, Iraj B, Sarrafzadegan N. "Socioeconomic disparities and controlling fasting plasma glucose in diabetic patients". Acta Biomedica.
3. Haidary Sardabi E, Majoor Z, Sadeghi M, Pourmoghadas M, Bahonar A, Sarrafzadegan N. "Association between the threshold sensitivity to salty taste and level of blood pressure salt-sensitivity in young Iranian normotensive individuals". ARYA Atherosclerosis
4. Behnemoon M, Sadeghi M, Garakyaraghi M, Koushkzari M, Naghnaian M, Sarrafzadegan N. "Association between air pollutants and heart failure symptom exacerbation leading to hospitalization". ARYA Atherosclerosis.
5. Roohafza H, Heidari K, Alinia T, Omidi R, Sadeghi M, Andalib E, Ajami A, Sarrafzadegan N. "Prevalence and motivational causes of smoking (cigarette and waterpipe) among Iranian adolescence; Results of ITUPP study". The Scientific World Journal.
6. Gharipour M, Khosravi A, Gharipour A, Ahmadi A, Sarrafzadegan N. "The value of salt intake to predict metabolic syndrome: A population base study in Iran". Endocrinology Journal

7. Soltani R, Keshvari M, Zolghadr M, Asgary S, Sahebkar A, Sarrafazadegan N. “Protective Effects of Hibiscus Sabdariffa on Metabolic Syndrome : a randomized, double-blind, placebo-controlled clinical trial”.
8. Sarrafazadegan N, Salehi-Abargouei A, Lotfizadeh M, Khosravi-Boroujeni H. “Magnesium and the metabolic syndrome: a systematic review and meta-analysis”. Nutrition Journal 2014.
9. Khosravi AR, Mohammadifard N, Sarrafazadegan N. “Validation of spot urine method with standard 24hours urine collection test to determine urinary sodium excretion: Results from Isfahan Salt Study”. Preventing Chronic Disease J. 2014.
10. Mousavi M, Sadeghi M, Porheidar B, Bidram P, Naderi Boldaji R, Bahonar A, Heidari E, Mahjoor Z, Sarrafazadegan N. “Association of positive family history for hypertension and salt sensitivity of blood pressure in normotensive individuals”. Iranian Heart Journal.
11. Sarrafazadegan N, Rabiei K, Alavi M, Golshahi J, Kelishadi R, et al. “Policy makers' viewpoints about implementation of the WHO-Framework Convention on Tobacco Control in Iran: A qualitative investigation on the program facilitators”. Slovenian Journal of Public Health.
12. Asgary S, Movahedian A, Sahebkar A, Taleghani M, Badiie A, Sarrafazadegan N. “Lead, Mercury and Cadmium in Relation to Coronary Artery Disease”. ARYA Atheroscler.
13. Mohammadifard N, Talaei M, Sadeghi M, Oveisgharan SH, Esmailzadeh A, Sarrafazadegan N. “Dietary patterns and mortality from cardiovascular disease: Isfahan Cohort Study”. Journal of Clinical Nutrition.
14. Mohammadifard N, Mansourian M, Sajjadi F, Maghroun M, Sarrafazadegan N. “Association of glycemic index and glycemic load with metabolic syndrome among Iranian adult population; Isfahan Healthy Heart Program”. Journal of Nutrition & Dietetics.
15. Abdolazimi M, Khosravi A, Sadeghi M, Mohammadian-hafshejani A, Sarrafazadegan N, Golshahi J. “Predictive factors of short-term survival from acute myocardial infarction in Early and Late Patients in Isfahan and Najaf Abad, Iran”. ARYA Atheroscler.
16. Golshahi J, Khales S, Sadeghi M, Sarrafazadegan N, Gharipour M, Dianatkhah M, Salehi A. “Can C-reactive protein and fibrinogen predict major adverse cardiac events in cardiovascular and cerebrovascular patients?”. Research in Cardiovascular Medicine.
17. Sadeghi M, Talaei M, Gharipour M, Oveisgharan Sh, Sarrafazadegan N. “Anthropometric indices predicting incident Hypertension in an Iranian population: The Isfahan Cohort Study”. (Drafted)
18. Sadeghi M, Badi M, Fallah-Mashkani R, Pourmoghaddas Z, Mohammadifard N, Afsahi Sh, Sarrafazadegan N. “The relationship between calcium, potassium, magnesium and sodium intake and salt sensitivity in subjects with normal blood pressure”. ARYA Atheroscler.
19. Sadeghi M, Gharipour M, Sarrafazadegan N, Shafie D, Aghababaie E. “Alteration of resting and maximum heart rates in metabolic syndrome”. Research in Cardiovascular Medicine.
20. Sadeghi M, Kermani-Alghoraishi M, Talaei M, Oveisgharan Sh, Sarrafazadegan N. “Prolongation of PR and QTC interval and prediction of cardiovascular events and mortality”. ARYA Atheroscler.
21. Dadjou Y, Sadeghi M, Kermani-Alghoraishi M, Talaei M, Yousefy A, Oveisgharan Sh, Sarrafazadegan N. “The Impact of Health-Related Quality of Life on the Incidence of Ischemic Heart Disease and Stroke; A Cohort Study in An Iranian Population”. Acta Cardiologica.
22. Gharipour M, Sadeghi M, Dianatkhah M, Sarrafazadegan N. “Triglyceride/High-Density Lipoprotein Cholesterol Concentration versus Metabolic Syndrome Criteria to Identifying Cardiovascular Disease Risk and Outcome”. (Drafted)

23. Gharipour M, Sadeghi M, Dianatkah M, Sarrafzadegan N. "Ability of Plasma Triglyceride/High-Density Lipoprotein Cholesterol Concentration to Predict Cardiovascular Disease Outcome". *Clinical Lipidology*.
24. Khosravi A, Ahmadzadeh S, Gharipour M, Golshahi J, Sadeghi M, Talaie M, Oveisgharan Sh, Sarrafzadegan N. "Is there any relationship between different phenotypes of metabolic syndrome and all cause mortality rate?". *ABR*.
25. Ahmadi A, Gharipour M, Heidari E, Navabi F, Sarrafzadegan N. "Main correlates of congenital heart defects". *Cardiology in the Young*.
26. Sarrafzadegan et al. "Pre-hypertension, pre-diabetes or both: Which is best at predicting cardiovascular events over the long term?". *Journal of Human Hypertension*.
27. Sarrafzadegan N, Gotay C, Laatikainen T, Kerner JF, Yach D, Puska P. "Isfahan Healthy Heart Program": a practical model of implementation and Knowledge Utilization in a developing country.

Presentations in International Congresses / Seminars / Conferences:

1. Sarrafzadegan N, et al. "The relation between education level, economic status and coronary artery disease in women" In: XII World Congress of Cardiology (Sep10-Sep14), Berlin: Germany, 1994.
2. Sarrafzadegan N, et al. "Prevalence of hypertension in Isfahan" In: The 4th International Conference on Preventive Cardiology (June 29 - July 3), Montreal: Canada, 1997.
3. Sarrafzadegan N, et al. "Prevalence of ischemic hearth disease in Isfahan" In: The 4th International Conference on Preventive Cardiology (June 29 - July 3), Montreal: Canada, 1997.
4. Sarrafzadegan N, et al. "Difference between the effects of passive smoking on fibrinogen and lipids of coronary patients and healthy people" In: The 4th International Conference on Preventive Cardiology (June 29 - July 3), Montreal: Canada, 1997.
5. Sarrafzadegan N, et al. "The effect of passive smoking among adolescents and its relation to the education and socioeconomic status of parents in Isfahan, Iran" In: The 10th World Conference on Tobacco & Health (August 24- 28), Beijing: China, 1997.
6. Sarrafzadegan N, et al. "The effect of smoking on the response of blood pressure to exercise and physical activity" In: The 10th World Conference on Tobacco & Health (August 24- 28), Beijing: China, 1997.
7. Sarrafzadegan N, et al. "The prevalence of current smoking among Iranian adolescents estimated by plasma cotinine" In: The 10th World Conference on Tobacco & Health (August 24- 28), Beijing: China, 1997.
8. Sarrafzadegan N, et al. "The effects of smoking on serum lipids and blood pressure response to rehabilitation exercise of cardiac patients" In: The 10th World Conference on Tobacco & Health (August 24- 28), Beijing: China, 1997.
9. Sarrafzadegan N, et al. "The effects of smoking on mean systolic blood pressure" In: The 10th World Conference on Tobacco & Health (August 24- 28), Beijing: China, 1997.
10. Sarrafzadegan N, et al. "Sex- specific distribution of coronary heart disease risk factors in Isfahan, Iran" In: The 1st Eastern Mediterranean Congress on Preventive Cardiology and 10th Annual Iranian Congress of Cardiovascular Diseases (May 2-5), Isfahan: Iran, 1997.

11. Sarrafzadegan N, et al. "Relationship of pathologic coronary atherosclerotic lesions to serum cholesterol in young people in Isfahan/Iran" In: The 1st Congress of the Asian-Pacific Society of Atherosclerosis and Vascular Disease (March 14-18), Taipei: Taiwan, 1998.
12. Sarrafzadegan N, et al. "Antihyperlipidemic effect of crataegus curvisepala lind" In: The 1st Congress of the Asian-Pacific Society of Atherosclerosis and Vascular Disease (March 14-18), Taipei: Taiwan, 1998.
13. Sarrafzadegan N, et al. "The relation between serum fibrinogen and magnesium with relative index of CPK-MB/CPK activity in myocardial infarction" In: The 13th Biennial Congress of Cardiology (Dec 3-6), Karachi: Pakistan, 1997.
14. Sarrafzadegan N, et al. "Health promotion in primary and secondary prevention of coronary artery diseases" In: The Cardiology Update Congress (Sep 8-10): Oslovak, 1997.
15. Sarrafzadegan N, et al. "The relation between left ventricular thickness and pathologic multiple coronary lesions in young and middle aged people in Isfahan" In: XIII World Congress of Cardiology (April 26-30): Rio De Janeiro: Brazil, 1998.
16. Sarrafzadegan N, et al. "Monocyte count as a risk factor for coronary heart disease" In: XIII World Congress of Cardiology (April 26-30): Rio De Janeiro: Brazil, 1998.
17. Sarrafzadegan N, et al. "Trend of cardiovascular disease mortality in Isfahan/Iran 1981 1994" In: XIII World Congress of Cardiology (April 26-30): Rio De Janeiro: Brazil, 1998.
18. Sarrafzadegan N, et al. "The relation between vitamin D level and Apo A1 and Apo B-100 in high risk children" In: XIII International Symposium on Drugs Affecting Lipid Metabolism (May 30- June3), Florence: Italy, 1998.
19. Sarrafzadegan N, et al. "Smokers: Why do they start and continue smoking?" In: 2nd European Conference on Tobacco or Health (Feb 23rd 27th). Las Palmas de Grand Canaria, Spain, 1999.
20. Sarrafzadegan N, et al. "Governmental and non-governmental collaboration with the regional (Quit and Win) contest in Isfahan 1998" In: 2nd European Conference on Tobacco or Health (Feb 23rd 27th), Las Palmas de Grand Canaria, Spain, 1999.
21. Sarrafzadegan N, et al. "Abdominal obesity and lipoprotein disturbances" In: 71st EAS Congress (May 26-29), Athena ,Greece, 1999.
22. Sarrafzadegan N, et al. "Hypertension and dyslipidemia among Iranian" In 71st EAS Congress (May 26-29), Athena, Greece, 1999.
23. Sarrafzadegan N, et al. "The effect of fasting during the month of holy Ramadan on apolipoproteins and coagulation system" In: 71st EAS Congress (May 26-29), Athena, Greece, 1999.
24. Sarrafzadegan N, et al. "Central obesity, nutritional status and lipid disturbances among Iranian women" In: 71st EAS Congress (May 26-29), Athena,Greece, 1999.
25. Sarrafzadegan N, et al. "The relation between thrombosis factors, plasma lipids and other risk factors in an Iranian sample" In: International Congress on Atherosclerosis, Hypertension & Coronary Artery Disease (14-16 Oct), New Delhi, India, 1999.
26. Sarrafzadegan N, et al, "The indicators of non-adherence to cardiac rehabilitation program in Iran". In: The 7th world congress of cardiac rehabilitation and secondary prevention (20-24 Feb), Manila, Philippines, 2000.
27. Sarrafzadegan N, et al. "Menopausal effect on the relation between haemostaic factors and lipoprotein levels." In: The First International Conference on Women, Heart Disease and Stroke. (7-10 May), Victoria, Canada, 2000.

28. Sarrafzadegan N, Mohammadifard N. "The effect of menopause on the relation between high triglyceride and low HDL-cholesterol with obesity". In: The XIIth International Symposium on Atherosclerosis (15-29 June), Stockholm, Sweden, 2000.
29. Sarrafzadegan N, Amiri M, Magsoodloo. "The association between antibody titers to Helicobacter pylori chronic coronary heart disease and acute myocardial infarction". In: The XIIth International Symposium on Atherosclerosis (15-29 June), Stockholm, Sweden, 2000.
30. Sarrafzadegan N, "Action on tobacco in Iran: The Tobacco control policies". In: The 11th World Conference on Tobacco or Health (6-11 August), Chicago, U.S.A, 2000.
31. Sarrafzadegan N, "Tobacco use among women and young people in the Eastern Mediterranean Region" In: The 11th World Conference on Tobacco or Health (6-11 August), Chicago, U.S.A, 2000.
32. Sarrafzadegan N, Rabiei K. "Gender difference in Cardiac Rehabilitation program among Iranian cardiac patients" In: The 5th International Congress on Preventive Cardiology (27-31 May) Osaka, Japan, 2001.
33. Sarrafzadegan N, Jalali A, et al. "Sex based relationship between some traditional and new risk factors in an Iranian sample". In: The 5th International Congress on Preventive Cardiology (27-31 May) Osaka, Japan, 2001.
34. Sarrafzadegan N, Kelishadi R, Mohamadifard N, Rabiei R. "Gender - specific issues in metabolic syndrome in Iranian women". In: XIV International Symposium on Atherosclerosis, Italy, 2006.
35. Sarrafzadegan N, Shahrokhi Sh, Kelishadi R, Roohafza HR, Mollabashi R. "Trends in one-month and one-year abstinence rates among smokers in four anti-smoking campaigns (1998-2004)". Washington, U.S.A, 2006.
36. Sarrafzadegan N, Sadri G, Malek-Afzali H. "Effect of a 6-year comprehensive community-based program on cardiovascular risk factors: experiences from demonstration study in a developing country". In: World Congress of Cardiology -Scientific Sessions, Beijing, China, Jun 16-19, 2010.
37. Sarrafzadegan N, Rabiei K, Sadri G. "Process evaluation of community-based interventions for prevention and control of cardiovascular diseases: A neglected area of evaluation". In: World Congress of Cardiology -Scientific Sessions, Beijing, China, Jun 16-19, 2010.
38. Sarrafzadegan N, Rabiei K, Zarfeshani S. "Lessons learnt from failures: experiences of demonstration program for cardiovascular disease prevention and control". In: World Congress of Cardiology -Scientific Sessions, Beijing, China, Jun 16-19, 2010.